aspirin has been researched along with Sinusitis in 264 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Sinusitis: Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)." | 9.30 | Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019) |
| "Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)." | 9.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 9.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| "Patients with asthma who have aspirin sensitivity have greater cysteinyl leukotriene production and greater airway hyperresponsiveness to the effects of inhaled cysteinyl leukotrienes than their aspirin-tolerant counterparts." | 9.10 | Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. ( Corrigan, CJ; Lee, TH; Parikh, A; Scadding, G; Sousa, AR, 2002) |
| "Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps." | 8.93 | Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 8.91 | Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant." | 8.90 | Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014) |
| "Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)." | 8.90 | Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014) |
| "The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease." | 8.89 | Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013) |
| "This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients." | 8.87 | Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011) |
| "NSAIDs-including aspirin (ASA)-that inhibit cyclooxygenase (COX)-1 induce nonallergic hypersensitivity reactions consisting of attacks of rhinitis and asthma." | 8.85 | Aspirin sensitivity and desensitization for asthma and sinusitis. ( Stevenson, DD, 2009) |
| "The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma." | 8.85 | Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)." | 8.84 | The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008) |
| "Interesting findings relating to aspirin-induced asthma recently emerged." | 8.81 | Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001) |
| "Aspirin-sensitive rhinosinusitis is a non-allergic, non-infectious perennial eosinophilic rhinitis starting in middle age and rarely seen in children." | 8.79 | Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. ( Schapowal, AG; Schmitz-Schumann, M; Simon, HU, 1995) |
| "Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions." | 8.77 | Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989) |
| "Aspirin-exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin-tolerant asthma (ATA)." | 8.31 | Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort. ( Kim, C; Lee, E; Lee, HY; Lee, Y; Park, HS; Park, RW; Woo, SD; You, SC, 2023) |
| " The coexistence of CRS, bronchial asthma and aspirin intolerance (aspirin triad) is an adverse prognostic factor with higher risk of recurrences." | 7.91 | Analysis of the impact of bronchial asthma and hypersensitivity to aspirin on the clinical course of chronic sinusitis with nasal polyps. ( Dąbrowska, K; Fendler, W; Pagacz, K; Pietruszewska, W; Podwysocka, M, 2019) |
| " Aspirin-exacerbated respiratory disease (AERD) is defined as asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors." | 7.85 | Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease. ( Johal, K; Peters, A; Welch, K, 2017) |
| "Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD)." | 7.85 | Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. ( Cutrera, R; Di Marco, A; Porcaro, F, 2017) |
| " In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population." | 7.81 | A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015) |
| "Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)." | 7.78 | Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012) |
| "The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis." | 7.77 | [The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011) |
| "Among the patients with asthma, polymorphism at -1082A/G was significantly associated with the phenotype of aspirin-intolerant asthma, AIA (P = 0." | 7.75 | Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. ( Cho, BY; Kim, SH; Lee, HN; Park, HS; Yang, EM; Ye, YM, 2009) |
| "Without prior exposure to aspirin or NSAIDs, the chance of a positive OAC was 5 in 12 (42%) but was 198 in 231 (86%) for those with a history of aspirin- and NSAID-associated asthma attacks." | 7.74 | Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. ( Dursun, AB; Karasoy, D; Simon, RA; Stevenson, DD; Woessner, KA, 2008) |
| "Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)." | 7.74 | Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007) |
| "To identify genes whose expression is most characteristic of chronic rhinosinusitis and aspirin-sensitive asthma through genome-wide transcriptional profiling of nasal polyp tissue." | 7.74 | Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. ( Goldsztein, H; Metson, R; Platt, MP; Reh, DD; Stankovic, KM, 2008) |
| "Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease." | 7.73 | Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005) |
| "Data were compared between asthmatic patients who reported exacerbations after aspirin ingestion and those who did not." | 7.73 | Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. ( Borish, L; Hunt, J; Mascia, K; Patrie, J; Phillips, CD; Steinke, JW, 2005) |
| "To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis." | 7.73 | Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006) |
| "The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)." | 7.72 | Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004) |
| "Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA." | 7.71 | A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002) |
| "Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis." | 7.71 | Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002) |
| "The aspirin triad (nasal polyposis, asthma and sensitivity to aspirin) is a well-recognized clinical entity, also known as aspirin-induced asthma (AIA)." | 7.70 | Effects of sinus surgery on asthma in aspirin triad patients. ( Higuchi, Y; Kawasaki, M; Nakamura, H; Takahashi, S, 1999) |
| "This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance." | 7.70 | [Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999) |
| "The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease." | 7.70 | [Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000) |
| " In contrast, the sinusitis of the aspirin triad syndrome is often fulminate, expansive, and recurrent, and complications may be more frequent." | 7.69 | Orbital complications of sinusitis in the aspirin triad syndrome. ( Massaro, BM; McFadden, EA; Toohill, RJ; Woodson, BT, 1996) |
| "Aspirin-sensitive patients with asthma experience continuous inflammation of their nasal and sinus tissues, complicated by recurrent sinusitis, which frequently leads to asthma attacks." | 7.69 | Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. ( Christiansen, SC; Hankammer, MA; Mathison, DA; Simon, RA; Stevenson, DD, 1996) |
| "We attempted to determine the relationship of nasal polyps to histamine (HA) metabolism." | 7.68 | Histamine metabolism in nasal polyps. ( Abe, Y; Fukui, H; Harada, T; Imamura, I; Irifune, M; Matsunaga, T; Ogino, S, 1993) |
| "An 11-year retrospective study was conducted to evaluate the surgical treatment of sinusitis in aspirin-triad patients." | 7.68 | Surgery for sinusitis and aspirin triad. ( Fink, JN; Kany, RJ; McFadden, EA; Toohill, RJ, 1990) |
| "One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988." | 7.68 | Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990) |
| "Nearly 700 specimens of polyps and sinus tissues from 12 patients with asthma and aspirin idiosyncrasy were studied with histochemical and immunofluorescent immunoglobulin techniques." | 7.67 | Histopathology and immunofluorescent immunoglobulins in asthmatics with aspirin idiosyncrasy. ( Carr, R; English, GM; Farr, R; Spector, S, 1987) |
| "Seventy-four asthmatic patients seen in a hospital were challenged with aspirin." | 7.67 | Prevalence of aspirin intolerance in asthmatics treated in a hospital. ( Castillo, JA; Picado, C, 1986) |
| "This study attempted to determine whether or not nasal and sinus surgery had a beneficial or deleterious effect upon the asthma of patients with nasal polyps and aspirin idiosyncrasy." | 7.67 | Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy. ( English, GM, 1986) |
| "In order to determine the types of respiratory responses observed during aspirin-induced reactions, 50 consecutive asthmatic patients with a history of aspirin sensitivity underwent prospective oral aspirin challenges between 1979 and 1981." | 7.66 | Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. ( Mathison, DA; Pleskow, WW; Schatz, M; Simon, RA; Stevenson, DD; Zeiger, RS, 1983) |
| "Aspirin-sensitive asthma is not well documented in children." | 7.66 | Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982) |
| "Chronic rhinosinusitis with nasal polyposis may be a symptom of aspirin-intolerance." | 7.65 | [Rhinosinusitis polyposa as the only symptom of aspirin intolerance -- a rhinorheomanometric diagnosis (author's transl)]. ( Enzmann, H; Kühn, H, 1977) |
| " We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events." | 6.82 | Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. ( Bousquet, J; Brignardello-Petersen, R; Chu, DK; Kennedy, DW; Oykhman, P; Paramo, FA, 2022) |
| "Sinusitis is very common, so it is important to understand its pathophysiology, diagnosis, and medical and surgical treatments." | 6.43 | Sinusitis: allergies, antibiotics, aspirin, asthma. ( Radojicic, C, 2006) |
| "Aspirin sensitivity has a highly significant association with AFRS." | 5.48 | Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by abnormal arachidonic acid metabolism leading to chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, and upper and/or lower respiratory symptoms after ingestion of cyclooxygenase-1 inhibiting nonsteroidal antiinflammatory drugs." | 5.41 | Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review. ( Choby, G; Divekar, RD; Hagan, JB; O'Brien, EK; Pinheiro-Neto, CD; Stokken, JK; Walters, BK; Willson, TJ, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic respiratory condition characterized by severe chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic asthma, and respiratory reactions to cyclooxygenase inhibitors." | 5.41 | Aspirin-exacerbated respiratory disease: Updates in the era of biologics. ( Buchheit, KM; Mullur, J, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by eosinophilic rhinosinusitis, nasal polyposis, and bronchial asthma, along with the onset of respiratory reactions after the ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA)." | 5.41 | Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial. ( Patel, KB; Rocha, T; Rotenberg, BW; Schmerk, C; Sommer, DD; Sowerby, LJ, 2021) |
| "These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity." | 5.30 | Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. ( Bardin, P; Bateman, ED; Garin, M; Germinaro, M; Hoyte, FCL; Katial, RK; Korn, S; McDonald, M; Weinstein, SF, 2019) |
| "Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)." | 5.30 | Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019) |
| "of our patients with bronchial asthma." | 5.27 | [Inhalation provocation test with lysine acetylsalicylic acid (Aspisol)--a useful method for the diagnosis of analgesic asthma]. ( Kirsten, D; Meister, W; Treutler, D, 1984) |
| "Aspirin exacerbated respiratory disease (AERD) is comprised of aspirin/acetylsalicylic acid (ASA) sensitivity, bronchial asthma, and nasal polyposis." | 5.20 | Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. ( Au, M; Gupta, MK; Hoffbauer, S; Nayan, S; Sommer, DD; Sowerby, LJ, 2015) |
| "Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)." | 5.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "To determine acute analgesia by acetylsalicylic acid (ASA) when combined with pseudoephedrine (PSE) in patients with upper respiratory tract infection (URTI), we used the sore throat pain model to measure single-dose effects of ASA 500 mg/PSE 30 mg, ASA 1000 mg/PSE 60 mg, and acetaminophen (APAP) 1000 mg/PSE 60 mg (serving as a positive control)." | 5.14 | Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. ( Becka, M; Bey, M; Gagney, D; Sanner, KM; Schachtel, BP; Schachtel, EJ; Voelker, M, 2010) |
| "Twenty-one adult patients with asthma, chronic polypoid sinusitis, and a convincing history of acute respiratory reaction to the ingestion of aspirin or nonsteroidal anti-inflammatory drugs were selected." | 5.14 | The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. ( Alam, R; Katial, RK; Leung, R; Prasertsuntarasai, T; Strand, M; Zheng, W, 2010) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 5.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is a condition composed of chronic rhinosinusitis with nasal polyposis and asthma that is defined by respiratory hypersensitivity reactions to the cyclooxygenase 1-inhibitory effects of nonsteroidal anti-inflammatory drugs." | 5.12 | Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. ( Haque, R; Hopkins, C; Jackson, DJ; White, AA, 2021) |
| "Patients with asthma who have aspirin sensitivity have greater cysteinyl leukotriene production and greater airway hyperresponsiveness to the effects of inhaled cysteinyl leukotrienes than their aspirin-tolerant counterparts." | 5.10 | Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. ( Corrigan, CJ; Lee, TH; Parikh, A; Scadding, G; Sousa, AR, 2002) |
| "Aspirin-exacerbated respiratory disease (AERD) represents an aggressive form of chronic rhinosinusitis with nasal polyposis that is notoriously challenging to treat." | 5.05 | Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review. ( Chin, CJ; Larivée, N, 2020) |
| "NSAID-Exacerbated respiratory disease (also known as Samter's or Widal's triad, aspirin-exacerbated respiratory disease) is characte- rized by asthma, nasal polyposis and hypersensitivity to NSAIDs." | 5.05 | [Widal's triad : clinical manifestations, pathophysiology and therapeutic advances]. ( Jandus, P; Landis, BN; Vandenberghe-Dürr, S, 2020) |
| "Aspirin-exacerbated respiratory disease is a chronic and treatment-resistant disease, characterized by the presence of eosinophilic rhinosinusitis, nasal polyposis, bronchial asthma, and nonsteroidal anti-inflammatory drugs hypersensitivity." | 4.98 | Aspirin exacerbated respiratory disease: Current topics and trends. ( Guaní-Guerra, E; Moreno-Paz, FJ; Rodríguez-Jiménez, JC; Terán, LM, 2018) |
| "Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs." | 4.95 | Aspirin-exacerbated respiratory disease and current treatment modalities. ( Cingi, C; Kar, M; Muluk, NB; Sakalar, EG, 2017) |
| "Aspirin-exacerbated respiratory disease (AERD) represents a severe form of chronic rhinosinusitis (CRS) characterized by nasal polyposis, bronchial asthma, and aspirin intolerance." | 4.93 | The Role of Surgery in Management of Samter's Triad: A Systematic Review. ( Adelman, J; Krouse, JH; McLean, C; Shaigany, K, 2016) |
| "Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps." | 4.93 | Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016) |
| "Aspirin-exacerbated respiratory disease is defined by the clinical tetrad of aspirin sensitivity, nasal polyps, asthma, and chronic rhinosinusitis." | 4.93 | Current complications and treatment of aspirin-exacerbated respiratory disease. ( Cook, KA; Stevenson, DD, 2016) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.91 | Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Aspirin-exacerbated respiratory disease is a clinical entity comprising chronic rhinosinusitis with nasal polyposis, asthma and intolerance to COX-1 inhibiting drugs." | 4.91 | Aspirin-exacerbated respiratory disease: characteristics and management strategies. ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Hypersensitivity to acetylsalicylic acid (ASA) is characterized by the co-occurrence of symptoms so-called aspirin triad, which include bronchial asthma, chronic rhinitis and sinusitis and the nasal mucosa polyps." | 4.91 | [Hypersensitivity to acetylsalicylic acid]. ( Skrętkowicz, J; Wojtczak, A, 2015) |
| " Several clinical phenotypes often leading to uncontrolled disease, including adult nasal polyposis, aspirin-exacerbated respiratory disease, and allergic fungal rhinosinusitis, are characterized by a common endotype: a TH2 bias is associated with a higher likelihood of comorbid asthma and recurrence after surgical treatment." | 4.91 | Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. ( Bachert, C; Gevaert, P; Zhang, L, 2015) |
| "Asthma has many triggers including rhinosinusitis; allergy; irritants; medications (aspirin in aspirin-exacerbated respiratory disease); and obesity." | 4.90 | Identifying asthma triggers. ( Ferguson, BJ; McCarty, JC, 2014) |
| "Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant." | 4.90 | Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014) |
| "Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)." | 4.90 | Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014) |
| "The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease." | 4.89 | Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013) |
| "This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients." | 4.87 | Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011) |
| "NSAIDs-including aspirin (ASA)-that inhibit cyclooxygenase (COX)-1 induce nonallergic hypersensitivity reactions consisting of attacks of rhinitis and asthma." | 4.85 | Aspirin sensitivity and desensitization for asthma and sinusitis. ( Stevenson, DD, 2009) |
| "The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma." | 4.85 | Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)." | 4.84 | The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008) |
| "In up to 10% of patients with bronchial asthma, aspirin and other nonsteroidal antiinflammatory drugs precipitate asthmatic attacks." | 4.82 | Aspirin intolerance and the cyclooxygenase-leukotriene pathways. ( Kiełbasa, B; Nizankowska-Mogilnicka, E; Sanak, M; Szczeklik, A, 2004) |
| "Recent findings supporting mechanisms that promote eosinophilic infiltration are discussed and include the following subcategories: super antigen-induced eosinophilic chronic rhinosinusitis, allergic fungal sinusitis, nonallergic fungal eosinophilic chronic rhinosinusitis, and aspirin-exacerbated eosinophilic chronic rhinosinusitis." | 4.82 | Categorization of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ, 2004) |
| " However, recently there has been some progress in elucidating the etiology of nasal polyposis, especially regarding tissue eosinophilia as well as the role of aspirin intolerance and eicosanoid mediators." | 4.82 | Current concepts in therapy of chronic rhinosinusitis and nasal polyposis. ( Gosepath, J; Mann, WJ, 2005) |
| "Interesting findings relating to aspirin-induced asthma recently emerged." | 4.81 | Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001) |
| "Aspirin-sensitive rhinosinusitis is a non-allergic, non-infectious perennial eosinophilic rhinitis starting in middle age and rarely seen in children." | 4.79 | Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. ( Schapowal, AG; Schmitz-Schumann, M; Simon, HU, 1995) |
| "Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions." | 4.77 | Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989) |
| "These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP)." | 4.31 | The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. ( Bernstein, JA; Bognanni, A; Chu, DK; Ellis, AK; Golden, DBK; Greenhawt, M; Horner, CC; Ledford, DK; Lieberman, J; Luong, AU; Orlandi, RR; Oykhman, P; Peters, AT; Rank, MA; Samant, SA; Shaker, MS; Soler, ZM; Stevens, WW; Stukus, DR; Wang, J, 2023) |
| "A total of 30 patients with AERD, 30 chronic rhinosinusitis (CRS) with NP patients without aspirin sensitivity (CRSwNP), and 30 control subjects without inflammation of the nasal mucosa (C), selected for surgical treatment entered the study." | 4.31 | Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity. ( Cvetković, G; Gaćeša, D; Perić, A; Vojvodić, D, 2023) |
| " Quantitative and descriptive analyses of age, gender, nationality, presence of polyps, aspirin sensitivity, presence of urticaria, asthma, and allergies were performed." | 4.31 | Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia. ( Alanazy, F; Alfallaj, R; Almousa, H; Aloulah, M; Alrasheed, A; Alromaih, S; Alroqi, AS; Alsaleh, S; Dousary, SA; Ismail, D; Mahjoub, S; Obaid, SB, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin-tolerant asthma (ATA)." | 4.31 | Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort. ( Kim, C; Lee, E; Lee, HY; Lee, Y; Park, HS; Park, RW; Woo, SD; You, SC, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) consists of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.31 | Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data. ( Adame, MJ; Kuo, YF; Raji, M; Shan, Y; Tripple, JW; Zhang, Y, 2023) |
| "The impact of anosmia on quality-of-life (QoL) for patients with aspirin-exacerbated respiratory disease (AERD) is poorly understood." | 4.12 | Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life. ( Bensko, JC; Buchheit, KM; Gakpo, D; Laidlaw, TM; Lundberg, M; Maurer, R; Mullur, J; Tchekmedyian, R, 2022) |
| "Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) is characterized by the triad of chronic rhinosinusitis with nasal polyp, asthma, and aspirin (ASA) or NSAID hypersensitivity." | 4.12 | Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease. ( Sompornrattanaphan, M; Tantilipikorn, P; Thongngarm, T; Wongsa, C, 2022) |
| "Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) asthma is characterized by chronic rhinosinusitis and intolerance of aspirin and other COX1 inhibitors." | 4.02 | Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. ( Bochenek, G; Gielicz, A; Jakiela, B; Plutecka, H; Przybyszowski, M; Rebane, A; Sladek, K; Soja, J, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is a syndrome characterised by chronic rhinosinusitis, nasal polyps, asthma and aspirin intolerance." | 4.02 | Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD). ( de Graaf, J; Gratziou, C; Jiménez-Chobillon, MA; Porras Gutiérrez de Velasco, R; Priyadharshini, VS; Ramírez-Jiménez, F; Teran, LM, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance." | 3.96 | The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. ( Eder, K; Gellrich, D; Gröger, M; Högerle, C; Pfrogner, E; San Nicoló, M, 2020) |
| "Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and acute respiratory tract reactions to ingestion of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)." | 3.96 | Aspirin-exacerbated respiratory disease: longitudinal assessment of a large cohort and implications of diagnostic delay. ( Chou, DW; Kshirsagar, RS; Liang, J; Wei, J, 2020) |
| "Aspirin-exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis." | 3.96 | Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. ( Cottrell, J; Grose, E; Lee, DJ; Lee, JK; Lee, JM; Sykes, J; Yip, J, 2020) |
| " CRSwNP may be associated with comorbidity, mainly concerning asthma, aspirin intolerance, and allergy." | 3.96 | Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice. ( Cassano, M; Ciprandi, G; Gelardi, M; Porro, G; Quaranta, N; Quaranta, V; Study Group On CRSwNP, I, 2020) |
| " The coexistence of CRS, bronchial asthma and aspirin intolerance (aspirin triad) is an adverse prognostic factor with higher risk of recurrences." | 3.91 | Analysis of the impact of bronchial asthma and hypersensitivity to aspirin on the clinical course of chronic sinusitis with nasal polyps. ( Dąbrowska, K; Fendler, W; Pagacz, K; Pietruszewska, W; Podwysocka, M, 2019) |
| "Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis." | 3.88 | Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. ( Waldram, JD; Walters, KM; White, AA; Woessner, KM, 2018) |
| " We also demonstrated that hypereosinophilia, asthma, and aspirin intolerance may increase the OR differently in eosinophilic patients." | 3.85 | Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? ( Autilio, C; Baroni, S; Battista, M; De Corso, E; De Vita, C; Galli, J; Lucidi, D; Paludetti, G; Romanello, M, 2017) |
| " Aspirin-exacerbated respiratory disease (AERD) is defined as asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors." | 3.85 | Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease. ( Johal, K; Peters, A; Welch, K, 2017) |
| "Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD)." | 3.85 | Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. ( Cutrera, R; Di Marco, A; Porcaro, F, 2017) |
| "Oral aspirin challenge (OAC) reveals aspirin-exacerbated respiratory disease (AERD) in approximately 50% of unselected patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)." | 3.85 | Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. ( Gudziol, V; Hummel, T; Koschel, D; Michel, M; Sonnefeld, C, 2017) |
| " In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population." | 3.81 | A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015) |
| "Aspirin-exacerbated respiratory disease (AERD), formerly known as Samter's Triad, is a syndrome of airway inflammation characterized by rhinosinusitis with polyposis, asthma, and nonsteroidal anti-inflammatory drug (NSAID) intolerance." | 3.81 | Samter's Triad to Aspirin-Exacerbated Respiratory Disease: Historical Perspective and Current Clinical Practice. ( Krouse, HJ; Krouse, JH, 2015) |
| "To demonstrate that quality-of-life outcomes after endoscopic sinus surgery are not compromised in patients with Samter's triad (asthma, nasal polyps, aspirin sensitivity) when compared to patients with eosinophilic chronic rhinosinusitis with nasal polyposis (eCRSwP) who are not aspirin sensitive." | 3.80 | Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. ( Comer, BT; Jang, DW; Kountakis, SE; Lachanas, VA, 2014) |
| " CRSwNP was subdivided into allergic fungal rhinosinusitis (AFRS), aspirin-exacerbated respiratory disease (AERD), and other CRSwNP." | 3.80 | Impact of vitamin D deficiency upon clinical presentation in nasal polyposis. ( Mulligan, JK; Schlosser, RJ; Schmedes, GW; Soler, ZM; Storck, K, 2014) |
| "Samter's triad is a well described condition manifesting as chronic rhinosinusitis with nasal polyposis, asthma and aspirin intolerance in a non-atopic individual." | 3.80 | Samter's triad with aural involvement: a novel approach to management. ( Heywood, R; Narula, A; Sethukumar, P, 2014) |
| " The impact of surgery and factors such as the presence of polyps, asthma, and aspirin sensitivity on the bacterial state are poorly understood." | 3.79 | The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients. ( Bassiouni, A; Cleland, EJ; Wormald, PJ, 2013) |
| "Aspirin-exacerbated respiratory disease (AERD) is distinguished from aspirin-tolerant asthma/chronic sinusitis in large part by an exuberant infiltration of eosinophils that are characterized by their overexpression of metabolic pathways that drive the constitutive and aspirin-induced secretion of cysteinyl leukotrienes (CysLTs)." | 3.79 | Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease. ( Borish, L; Huyett, P; Liu, L; Negri, J; Payne, SC; Steinke, JW, 2013) |
| "Patients with chronic rhinosinusitis (CRS) and nasal polyps (NPs) may be subdivided into aspirin-sensitive (AS) and aspirin-tolerant (AT) populations." | 3.79 | Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps. ( Fountain, CR; Katial, RK; Kingdom, TT; Mudd, PA; Ramakrishnan, VR; Sillau, SH, 2013) |
| "SPINK5 single-nucleotide polymorphisms (SNPs) and SPINK5 expression levels were correlated with CRS without (CRSsNP) and with nasal polyps (CRSwNP), aspirin intolerance, asthma, and allergies." | 3.78 | Low SPINK5 expression in chronic rhinosinusitis. ( Brieger, J; Fruth, K; Goebel, G; Gosepath, J; Koutsimpelas, D; Mann, WJ; Schmidtmann, I, 2012) |
| "Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)." | 3.78 | Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012) |
| "Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway inflammation that frequently occurs in patients with nasal polyposis, chronic sinusitis, and asthma." | 3.78 | Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. ( Stevenson, DD; White, AA, 2012) |
| "The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis." | 3.77 | [The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011) |
| "There is a well-recognized association of aspirin sensitivity, aspirin-induced asthma, nasal polyposis or sinusitis, known as Samter's triad." | 3.76 | Aspirin sensitivity and the nose. ( Douglas, GC; Karkos, PD; Swift, AC, 2010) |
| "It was the aim of this study to investigate the prevalence of otologic manifestations in a cohort of Samter's syndrome patients (nasal polyps with chronic rhinosinusitis, aspirin intolerance and asthma)." | 3.75 | Otologic manifestations in Samter's syndrome. ( Caversaccio, M; Häusler, R; Helbling, A, 2009) |
| "Among the patients with asthma, polymorphism at -1082A/G was significantly associated with the phenotype of aspirin-intolerant asthma, AIA (P = 0." | 3.75 | Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. ( Cho, BY; Kim, SH; Lee, HN; Park, HS; Yang, EM; Ye, YM, 2009) |
| "Airway eosinophilia is a hallmark of aspirin-sensitive asthma/rhinitis." | 3.75 | Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients. ( Fuentes-Beltrán, A; García-Cruz, Mde L; Montes-Vizuet, R; Negrete-García, MC; Teran, LM; Valencia-Maqueda, E, 2009) |
| " Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs." | 3.75 | Unmet needs in severe chronic upper airway disease (SCUAD). ( Bachert, C; Bousquet, J; Canonica, GW; Casale, TB; Cruz, AA; Lockey, RJ; Zuberbier, T, 2009) |
| "Without prior exposure to aspirin or NSAIDs, the chance of a positive OAC was 5 in 12 (42%) but was 198 in 231 (86%) for those with a history of aspirin- and NSAID-associated asthma attacks." | 3.74 | Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. ( Dursun, AB; Karasoy, D; Simon, RA; Stevenson, DD; Woessner, KA, 2008) |
| " Often it is associated with non allergic rhinitis with eosinophilia syndrome (NARES), nasal polyposis and intolerance to Aspirin and NSAID's." | 3.74 | [Nonallergic diseases of the upper and lower airways]. ( Menz, G; Rothe, T, 2008) |
| " In these cases, CRS tends to be associated with bronchial asthma (BA), especially, aspirin-intolerant asthma (AIA)." | 3.74 | Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. ( Haruna, S; Moriyama, H; Otori, N; Yoshikawa, M; Yoshimura, T, 2008) |
| "Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)." | 3.74 | Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007) |
| "Aspirin desensitization is indicated for patients who have aspirin-exacerbated respiratory disease and whose asthma and/or rhinosinusitis is suboptimally controlled with inhaled corticosteroids and leukotriene-modifying drugs." | 3.74 | Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. ( Bernstein, JA; Castells, MC; Gawchik, SM; Lee, TH; Macy, E; Settipane, RA; Simon, RA; Wald, J; Woessner, KM, 2007) |
| "We conducted a retrospective study to determine the prevalence of Samter's triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003." | 3.74 | The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. ( Kim, JE; Kountakis, SE, 2007) |
| " Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis." | 3.74 | BSACI guidelines for the management of rhinosinusitis and nasal polyposis. ( Dixon, TA; Drake-Lee, AB; Durham, SR; Huber, PA; Jones, NS; Mirakian, R; Nasser, SM; Ryan, D; Scadding, GK, 2008) |
| "To identify genes whose expression is most characteristic of chronic rhinosinusitis and aspirin-sensitive asthma through genome-wide transcriptional profiling of nasal polyp tissue." | 3.74 | Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. ( Goldsztein, H; Metson, R; Platt, MP; Reh, DD; Stankovic, KM, 2008) |
| "Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease." | 3.73 | Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005) |
| "Data were compared between asthmatic patients who reported exacerbations after aspirin ingestion and those who did not." | 3.73 | Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. ( Borish, L; Hunt, J; Mascia, K; Patrie, J; Phillips, CD; Steinke, JW, 2005) |
| "We have previously demonstrated that aspirin triggers specific generation of 15-hydroxyeicosateraenoic acid (15-HETE) from nasal polyp epithelial cells and peripheral blood leukocytes (PBL) from aspirin-sensitive (AS) but not aspirin-tolerant (AT) patients with asthma/rhinosinusitis." | 3.73 | Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). ( Bienkiewicz, B; Cieslak, M; Dubuske, L; Grzegorczyk, J; Jedrzejczak, M; Kowalski, ML; Pawliczak, R; Ptasinska, A, 2005) |
| "The blocking effect of controller medications for asthma could have an effect on the outcome of aspirin challenges in patients suspected of having aspirin-exacerbated respiratory disease (AERD)." | 3.73 | The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. ( Simon, RA; Stevenson, DD; White, AA, 2005) |
| "To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis." | 3.73 | Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006) |
| "The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)." | 3.72 | Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004) |
| "Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA." | 3.71 | A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002) |
| "Patients with aspirin-sensitive rhinosinusitis, which is frequently associated with intrinsic bronchial asthma, can be desensitized by long-term treatment with oral aspirin." | 3.71 | Individual monitoring of aspirin desensitization. ( Amedee, RG; Gosepath, J; Mann, WJ; Schaefer, D, 2001) |
| "Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis." | 3.71 | Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002) |
| "The aspirin triad (nasal polyposis, asthma and sensitivity to aspirin) is a well-recognized clinical entity, also known as aspirin-induced asthma (AIA)." | 3.70 | Effects of sinus surgery on asthma in aspirin triad patients. ( Higuchi, Y; Kawasaki, M; Nakamura, H; Takahashi, S, 1999) |
| "This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance." | 3.70 | [Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999) |
| "The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease." | 3.70 | [Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000) |
| " In contrast, the sinusitis of the aspirin triad syndrome is often fulminate, expansive, and recurrent, and complications may be more frequent." | 3.69 | Orbital complications of sinusitis in the aspirin triad syndrome. ( Massaro, BM; McFadden, EA; Toohill, RJ; Woodson, BT, 1996) |
| "Aspirin-sensitive patients with asthma experience continuous inflammation of their nasal and sinus tissues, complicated by recurrent sinusitis, which frequently leads to asthma attacks." | 3.69 | Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. ( Christiansen, SC; Hankammer, MA; Mathison, DA; Simon, RA; Stevenson, DD, 1996) |
| "We attempted to determine the relationship of nasal polyps to histamine (HA) metabolism." | 3.68 | Histamine metabolism in nasal polyps. ( Abe, Y; Fukui, H; Harada, T; Imamura, I; Irifune, M; Matsunaga, T; Ogino, S, 1993) |
| " ASA challenges were performed in 17 ASA-sensitive patients with asthma and rhinosinusitis, and tryptase and histamine levels were measured in their venous blood samples." | 3.68 | Tryptase and histamine release during aspirin-induced respiratory reactions. ( Bosso, JV; Schwartz, LB; Stevenson, DD, 1991) |
| "An 11-year retrospective study was conducted to evaluate the surgical treatment of sinusitis in aspirin-triad patients." | 3.68 | Surgery for sinusitis and aspirin triad. ( Fink, JN; Kany, RJ; McFadden, EA; Toohill, RJ, 1990) |
| "One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988." | 3.68 | Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990) |
| " Before immunotherapy, all patients had a complete evaluation of the severity of asthma by symptom-medication scores and a pulmonary function test, as well as a study of other triggering factors by checking on seasonal and perennial allergens, sinusitis, and other possible causes, such as aspirin intolerance; 196 patients were investigated between 9 and 12 months after the onset of the survey by means of pulmonary function tests and symptom-medication scores." | 3.67 | Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. ( Bousquet, J; Clauzel, AM; Dhivert, H; Guérin, B; Hejjaoui, A; Michel, FB; Skassa-Brociek, W, 1988) |
| "Nearly 700 specimens of polyps and sinus tissues from 12 patients with asthma and aspirin idiosyncrasy were studied with histochemical and immunofluorescent immunoglobulin techniques." | 3.67 | Histopathology and immunofluorescent immunoglobulins in asthmatics with aspirin idiosyncrasy. ( Carr, R; English, GM; Farr, R; Spector, S, 1987) |
| "Seventy-four asthmatic patients seen in a hospital were challenged with aspirin." | 3.67 | Prevalence of aspirin intolerance in asthmatics treated in a hospital. ( Castillo, JA; Picado, C, 1986) |
| "This study attempted to determine whether or not nasal and sinus surgery had a beneficial or deleterious effect upon the asthma of patients with nasal polyps and aspirin idiosyncrasy." | 3.67 | Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy. ( English, GM, 1986) |
| "In order to determine the types of respiratory responses observed during aspirin-induced reactions, 50 consecutive asthmatic patients with a history of aspirin sensitivity underwent prospective oral aspirin challenges between 1979 and 1981." | 3.66 | Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. ( Mathison, DA; Pleskow, WW; Schatz, M; Simon, RA; Stevenson, DD; Zeiger, RS, 1983) |
| "Aspirin-sensitive asthma is not well documented in children." | 3.66 | Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982) |
| "Chronic rhinosinusitis with nasal polyposis may be a symptom of aspirin-intolerance." | 3.65 | [Rhinosinusitis polyposa as the only symptom of aspirin intolerance -- a rhinorheomanometric diagnosis (author's transl)]. ( Enzmann, H; Kühn, H, 1977) |
| " We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events." | 2.82 | Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. ( Bousquet, J; Brignardello-Petersen, R; Chu, DK; Kennedy, DW; Oykhman, P; Paramo, FA, 2022) |
| "Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, which is not uncommon in patients with refractory CRS." | 2.46 | Rhinosinusitis and comorbidities. ( Brooks, EG; Ryan, MW, 2010) |
| "Chronic rhinosinusitis is often associated with bronchial asthma." | 2.45 | [Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options]. ( Jung, H, 2009) |
| "Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, and humoral immunodeficiency is not uncommon in patients with refractory chronic rhinosinusitis." | 2.44 | Diseases associated with chronic rhinosinusitis: what is the significance? ( Ryan, MW, 2008) |
| "Eosinophilia is frequently, but not exclusively, caused by immunoglobulin (Ig)E-mediated hypersensitivity and is dominated by the associated cytokine milieu of Th2 inflammation." | 2.43 | Differential diagnosis of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ; Sok, JC, 2006) |
| "Sinusitis is very common, so it is important to understand its pathophysiology, diagnosis, and medical and surgical treatments." | 2.43 | Sinusitis: allergies, antibiotics, aspirin, asthma. ( Radojicic, C, 2006) |
| "Ifetroban was well tolerated in AERD and did not change the mean 2-point increase in Total Nasal Symptom Score (P = ." | 1.91 | Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease. ( Boyce, JA; Buchheit, KM; Cahill, KN; Chen, CC; Cho, L; Cui, J; Feng, C; Hacker, J; Israel, E; Laidlaw, TM; Le, M, 2023) |
| "Aspirin treatment after desensitization (ATAD) represents an effective therapeutic option suitable for NSAID-exacerbated respiratory disease (N-ERD) patients with recalcitrant disease." | 1.72 | A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease. ( Andrews, PJ; Pendolino, AL; Scadding, GK; Scarpa, B, 2022) |
| "Treatment of aspirin-exacerbated respiratory disease (AERD) includes endoscopic sinus surgery (ESS) and aspirin desensitization (AD) with aspirin therapy after desensitization (ATAD)." | 1.62 | Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease. ( Adappa, ND; Bosso, JV; Civantos, AM; Corr, AM; Gleeson, PK; Ig-Izevbekhai, KI; Kohanski, MA; Kumar, A; Lin, TC; Locke, TB; Palmer, JN; Sweis, AM, 2021) |
| " Long-term administration of acetylsalicylic acid (ASA) after desensitization has been used to mitigate these sequelae, but the optimal dose and balancing symptom relief and side effects remain unsettled." | 1.56 | Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. ( Appel, H; Greve, J; Hahn, J; Hoffmann, TK; Lindemann, J; Petereit, F; Scheithauer, MO; Sommer, F; Veit, JA, 2020) |
| "Aspirin sensitivity has a highly significant association with AFRS." | 1.48 | Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018) |
| "Prednisone was the most common OCS prescribed." | 1.46 | Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership. ( Ernst, HM; Rotenberg, BW; Rudmik, L; Scott, JR; Sowerby, LJ, 2017) |
| "Sinusitis is both prevalent and costly, affecting more than 14% of the population and costing more than $3." | 1.30 | Medical management of sinusitis. ( Kaliner, M, 1998) |
| "Tissue eosinophilia was a prominent feature of both allergic and nonallergic CHS/NP and correlated in both subgroups with the density of GM-CSF and IL-3 mRNA+ cells." | 1.29 | Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. ( Bean, DK; Cunningham, L; Hamid, Q; Hamilos, DL; Leung, DY; Schotman, E; Wood, R; Yasruel, Z, 1995) |
| "of our patients with bronchial asthma." | 1.27 | [Inhalation provocation test with lysine acetylsalicylic acid (Aspisol)--a useful method for the diagnosis of analgesic asthma]. ( Kirsten, D; Meister, W; Treutler, D, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (11.36) | 18.7374 |
| 1990's | 17 (6.44) | 18.2507 |
| 2000's | 62 (23.48) | 29.6817 |
| 2010's | 78 (29.55) | 24.3611 |
| 2020's | 77 (29.17) | 2.80 |
| Authors | Studies |
|---|---|
| Pendolino, AL | 1 |
| Scadding, GK | 3 |
| Scarpa, B | 1 |
| Andrews, PJ | 1 |
| Oykhman, P | 2 |
| Paramo, FA | 1 |
| Bousquet, J | 3 |
| Kennedy, DW | 2 |
| Brignardello-Petersen, R | 1 |
| Chu, DK | 3 |
| Bertlich, M | 1 |
| Ihler, F | 1 |
| Bertlich, I | 1 |
| Weiss, BG | 1 |
| Gröger, M | 2 |
| Haubner, F | 1 |
| D'Souza, GE | 1 |
| Nwagu, U | 1 |
| Barton, B | 1 |
| Unsal, AA | 1 |
| Rabinowitz, MR | 1 |
| Rosen, MR | 1 |
| Nyquist, GG | 1 |
| Cohn, J | 1 |
| Most, J | 1 |
| Toskala, EM | 1 |
| Sehanobish, E | 3 |
| Asad, M | 2 |
| Jerschow, E | 4 |
| Talat, R | 1 |
| Gengler, I | 1 |
| Phillips, KM | 1 |
| Caradonna, DS | 1 |
| Gray, ST | 1 |
| Sedaghat, AR | 2 |
| Idler, BM | 1 |
| Lal, D | 1 |
| Marino, MJ | 1 |
| Patel, P | 1 |
| Bensko, JC | 9 |
| Bhattacharyya, N | 2 |
| Laidlaw, TM | 17 |
| Buchheit, KM | 14 |
| Wallace, DV | 1 |
| Ramos, CL | 1 |
| Woessner, KM | 4 |
| Stevens, WW | 4 |
| White, AA | 12 |
| Cahill, KN | 9 |
| Wu, P | 2 |
| Milne, GL | 1 |
| Amin, T | 1 |
| Singer, J | 2 |
| Murphy, K | 1 |
| Lewis, E | 2 |
| Gapko, D | 1 |
| Boyce, JA | 4 |
| Tan, LH | 1 |
| Lin, C | 1 |
| Ungerer, H | 1 |
| Kumar, A | 3 |
| Qatanani, A | 1 |
| Adappa, ND | 6 |
| Palmer, JN | 6 |
| Bosso, JV | 9 |
| Reed, D | 1 |
| Cohen, NA | 3 |
| Kohanski, MA | 6 |
| Miss Ozuna, L | 1 |
| Ryan, T | 1 |
| Mullur, J | 3 |
| Steger, CM | 1 |
| Gakpo, D | 4 |
| Maurer, R | 3 |
| Corey, KB | 2 |
| Turner, JH | 1 |
| Chowdhury, NI | 1 |
| Chandra, RK | 1 |
| Li, P | 1 |
| Bangert, C | 1 |
| Villazala-Merino, S | 1 |
| Fahrenberger, M | 1 |
| Krausgruber, T | 1 |
| Bauer, WM | 1 |
| Stanek, V | 1 |
| Campion, NJ | 1 |
| Bartosik, T | 1 |
| Quint, T | 1 |
| Regelsberger, G | 1 |
| Niederberger-Leppin, V | 1 |
| Bock, C | 1 |
| Schneider, S | 1 |
| Eckl-Dorna, J | 1 |
| Sohail, A | 1 |
| Hacker, J | 2 |
| Taliaferro, F | 1 |
| Ordovas-Montanes, J | 2 |
| Tchekmedyian, R | 1 |
| Lundberg, M | 1 |
| Pitlick, MM | 1 |
| Pongdee, T | 1 |
| Suikkila, A | 1 |
| Lyly, A | 1 |
| Hafrén, L | 1 |
| Saarinen, R | 1 |
| Klockars, T | 1 |
| McGill, A | 1 |
| Palumbo, M | 1 |
| Ghiasi, Y | 1 |
| Wangberg, H | 2 |
| Bagsic, SRS | 1 |
| White, A | 2 |
| Walters, BK | 1 |
| Hagan, JB | 1 |
| Divekar, RD | 1 |
| Willson, TJ | 1 |
| Stokken, JK | 1 |
| Pinheiro-Neto, CD | 1 |
| O'Brien, EK | 1 |
| Choby, G | 1 |
| Esmaeilzadeh, H | 2 |
| Zare, M | 1 |
| Alyasin, S | 1 |
| Nabavizadeh, H | 1 |
| Mortazavi, N | 2 |
| Kanannejad, Z | 1 |
| Rank, MA | 2 |
| Bognanni, A | 1 |
| Bernstein, JA | 2 |
| Ellis, AK | 1 |
| Golden, DBK | 1 |
| Greenhawt, M | 1 |
| Horner, CC | 1 |
| Ledford, DK | 1 |
| Lieberman, J | 1 |
| Luong, AU | 1 |
| Orlandi, RR | 1 |
| Samant, SA | 1 |
| Shaker, MS | 1 |
| Soler, ZM | 2 |
| Stukus, DR | 1 |
| Wang, J | 1 |
| Peters, AT | 2 |
| Perić, A | 3 |
| Gaćeša, D | 2 |
| Cvetković, G | 1 |
| Vojvodić, D | 1 |
| Tao, M | 1 |
| Roberts, S | 1 |
| Arnold, M | 1 |
| Candelo, E | 1 |
| McCalla, M | 1 |
| Valderrama, OA | 1 |
| Avila-Castano, K | 1 |
| Chelf, C | 1 |
| Olomu, O | 1 |
| Donaldson, AM | 1 |
| Hayashi, H | 2 |
| Fukutomi, Y | 2 |
| Mitsui, C | 2 |
| Kajiwara, K | 2 |
| Watai, K | 2 |
| Tomita, Y | 1 |
| Kamide, Y | 2 |
| Tsuburai, T | 1 |
| Sekiya, K | 2 |
| Ishii, M | 1 |
| Hasegawa, Y | 1 |
| Taniguchi, M | 5 |
| Alfallaj, R | 1 |
| Obaid, SB | 1 |
| Almousa, H | 1 |
| Ismail, D | 1 |
| Mahjoub, S | 1 |
| Alanazy, F | 1 |
| Dousary, SA | 1 |
| Alromaih, S | 1 |
| Aloulah, M | 1 |
| Alrasheed, A | 1 |
| Alroqi, AS | 1 |
| Alsaleh, S | 1 |
| Cho, L | 1 |
| Cui, J | 1 |
| Feng, C | 1 |
| Chen, CC | 1 |
| Le, M | 1 |
| Israel, E | 1 |
| Lee, Y | 1 |
| Kim, C | 1 |
| Lee, E | 1 |
| Lee, HY | 1 |
| Woo, SD | 1 |
| You, SC | 1 |
| Park, RW | 1 |
| Park, HS | 3 |
| Supron, AD | 1 |
| Bergmark, RW | 1 |
| Roditi, RE | 1 |
| Panara, K | 1 |
| Grose, E | 2 |
| Lee, DJ | 2 |
| Safadi, J | 1 |
| Douglas, JE | 1 |
| Lee, JM | 2 |
| Adame, MJ | 1 |
| Raji, M | 1 |
| Shan, Y | 1 |
| Zhang, Y | 1 |
| Kuo, YF | 1 |
| Tripple, JW | 1 |
| Herzberg, SD | 1 |
| Bosso, AM | 1 |
| Sangal, NR | 1 |
| Badrani, JH | 1 |
| Cavagnero, K | 1 |
| Eastman, JJ | 1 |
| Kim, AS | 1 |
| Strohm, A | 1 |
| Yan, C | 1 |
| Deconde, A | 1 |
| Zuraw, BL | 1 |
| Christiansen, SC | 2 |
| Doherty, TA | 1 |
| Kim, SL | 1 |
| Vukadinović, T | 1 |
| Vuksanović Božarić, A | 1 |
| Vukomanović Đurđević, B | 1 |
| Radunović, M | 1 |
| Lee, SE | 1 |
| Farquhar, DR | 1 |
| Adams, KN | 1 |
| Masood, MM | 1 |
| Senior, BA | 1 |
| Thorp, BD | 2 |
| Zanation, AM | 2 |
| Ebert, CS | 2 |
| San Nicoló, M | 1 |
| Högerle, C | 1 |
| Gellrich, D | 1 |
| Eder, K | 1 |
| Pfrogner, E | 1 |
| Wongsa, C | 1 |
| Sompornrattanaphan, M | 1 |
| Tantilipikorn, P | 1 |
| Thongngarm, T | 1 |
| Podwysocka, M | 1 |
| Dąbrowska, K | 1 |
| Fendler, W | 1 |
| Pagacz, K | 1 |
| Pietruszewska, W | 1 |
| Nelson, RK | 1 |
| Bush, A | 1 |
| Stokes, J | 1 |
| Nair, P | 1 |
| Akuthota, P | 1 |
| Larivée, N | 1 |
| Chin, CJ | 1 |
| Studer, MB | 1 |
| Roland, LT | 1 |
| Ochsner, MC | 1 |
| Cox, D | 1 |
| DelGaudio, JM | 1 |
| Wise, SK | 1 |
| Levy, JM | 6 |
| Kshirsagar, RS | 1 |
| Chou, DW | 1 |
| Wei, J | 1 |
| Liang, J | 1 |
| Dwyer, DF | 1 |
| Katz, HR | 1 |
| Vukovic, M | 1 |
| Lai, J | 1 |
| Bankova, LG | 1 |
| Shalek, AK | 1 |
| Barrett, NA | 2 |
| Hahn, J | 1 |
| Appel, H | 1 |
| Scheithauer, MO | 1 |
| Petereit, F | 1 |
| Greve, J | 1 |
| Lindemann, J | 1 |
| Hoffmann, TK | 1 |
| Veit, JA | 1 |
| Sommer, F | 1 |
| McHugh, T | 1 |
| Levin, M | 1 |
| Snidvongs, K | 1 |
| Banglawala, SM | 1 |
| Sommer, DD | 4 |
| Vandenberghe-Dürr, S | 1 |
| Landis, BN | 1 |
| Jandus, P | 1 |
| Chen, YS | 1 |
| Yip, J | 1 |
| Cottrell, J | 1 |
| Sykes, J | 1 |
| Lee, JK | 1 |
| Gelardi, M | 1 |
| Porro, G | 1 |
| Quaranta, V | 1 |
| Quaranta, N | 1 |
| Cassano, M | 1 |
| Ciprandi, G | 1 |
| Study Group On CRSwNP, I | 1 |
| Schlosser, RJ | 2 |
| Malfitano, MJ | 1 |
| Santarelli, GD | 1 |
| Gelpi, M | 1 |
| Brown, WC | 1 |
| Stepp, WH | 1 |
| Hernandez, S | 1 |
| Kimple, AJ | 1 |
| Sweis, AM | 2 |
| Locke, TB | 2 |
| Ig-Izevbekhai, KI | 1 |
| Lin, TC | 2 |
| Gleeson, PK | 2 |
| Civantos, AM | 2 |
| Corr, AM | 2 |
| Gakpo, DH | 1 |
| Buchheit, K | 1 |
| Parhar, HS | 1 |
| Salmon, MK | 1 |
| Jakiela, B | 1 |
| Soja, J | 1 |
| Sladek, K | 1 |
| Przybyszowski, M | 1 |
| Plutecka, H | 2 |
| Gielicz, A | 3 |
| Rebane, A | 1 |
| Bochenek, G | 2 |
| Cameli, P | 1 |
| D'Alessandro, M | 1 |
| Bergantini, L | 1 |
| Silvestri, E | 1 |
| Romaldi, A | 1 |
| Emmi, G | 1 |
| Parronchi, P | 1 |
| Bargagli, E | 1 |
| He, SC | 1 |
| Xu, YT | 1 |
| Baptist, AP | 1 |
| Borish, L | 4 |
| Campo, P | 1 |
| Cho, SH | 1 |
| Keswani, A | 1 |
| Nanda, A | 1 |
| Espersen, J | 1 |
| Weber, U | 1 |
| Römer-Franz, A | 1 |
| Lenarz, T | 1 |
| Stolle, SRO | 1 |
| Warnecke, A | 1 |
| Cook, KA | 2 |
| Domissy, A | 1 |
| Simon, RA | 12 |
| Modena, BD | 1 |
| Tripathi, SH | 1 |
| Bavaro, N | 1 |
| Mittal, A | 1 |
| Spierling Bagsic, SR | 1 |
| Sowerby, LJ | 3 |
| Patel, KB | 1 |
| Schmerk, C | 1 |
| Rotenberg, BW | 2 |
| Rocha, T | 1 |
| Kuruvilla, M | 1 |
| Bensko, J | 1 |
| Arshi, S | 2 |
| Darougar, S | 1 |
| Nabavi, M | 2 |
| Bemanian, MH | 2 |
| Fallahpour, M | 2 |
| Shokri, S | 1 |
| Ahmadian, J | 1 |
| Molatefi, R | 1 |
| Rekabi, M | 1 |
| Moinfar, Z | 1 |
| Hashemitari, P | 1 |
| Eslami, N | 1 |
| Barbi, M | 1 |
| Porcelli, SA | 1 |
| Haque, R | 1 |
| Jackson, DJ | 1 |
| Hopkins, C | 4 |
| Priyadharshini, VS | 1 |
| Jiménez-Chobillon, MA | 1 |
| de Graaf, J | 1 |
| Porras Gutiérrez de Velasco, R | 1 |
| Gratziou, C | 1 |
| Ramírez-Jiménez, F | 1 |
| Teran, LM | 3 |
| De Corso, E | 1 |
| Lucidi, D | 1 |
| Battista, M | 1 |
| Romanello, M | 1 |
| De Vita, C | 1 |
| Baroni, S | 1 |
| Autilio, C | 1 |
| Galli, J | 1 |
| Paludetti, G | 1 |
| Johal, K | 1 |
| Welch, K | 1 |
| Peters, A | 1 |
| Ranasinghe, VJ | 1 |
| Trope, M | 1 |
| Brooks, SG | 1 |
| Glicksman, JT | 1 |
| Parasher, AK | 1 |
| Rodríguez-Jiménez, JC | 1 |
| Moreno-Paz, FJ | 1 |
| Guaní-Guerra, E | 1 |
| Walters, KM | 1 |
| Waldram, JD | 3 |
| Philpott, CM | 1 |
| Erskine, S | 2 |
| Kumar, N | 2 |
| Anari, S | 2 |
| Kara, N | 2 |
| Sunkaraneni, S | 1 |
| Ray, J | 2 |
| Clark, A | 2 |
| Wilson, A | 1 |
| Philpott, C | 1 |
| Robertson, A | 1 |
| Ahmed, S | 1 |
| Carrie, S | 1 |
| Sunkaraneni, V | 1 |
| Jervis, P | 1 |
| Panesaar, J | 1 |
| Farboud, A | 1 |
| Cathcart, R | 1 |
| Almeyda, R | 1 |
| Khalil, H | 1 |
| Prinsley, P | 1 |
| Mansell, N | 1 |
| Salam, M | 1 |
| Hobson, J | 1 |
| Woods, J | 1 |
| Coombes, E | 1 |
| Yamaguchi, T | 1 |
| Ishii, T | 2 |
| Yamamoto, K | 1 |
| Higashi, N | 4 |
| Okamoto, M | 1 |
| Weinstein, SF | 1 |
| Katial, RK | 5 |
| Bardin, P | 1 |
| Korn, S | 1 |
| McDonald, M | 1 |
| Garin, M | 1 |
| Bateman, ED | 1 |
| Hoyte, FCL | 1 |
| Germinaro, M | 1 |
| Eid, RC | 1 |
| Palumbo, ML | 1 |
| DeGregorio, GA | 1 |
| Laidlaw, T | 1 |
| Kowalski, ML | 9 |
| Stevenson, DD | 18 |
| Cooper, T | 1 |
| Greig, SR | 1 |
| Zhang, H | 1 |
| Seemann, R | 1 |
| Wright, ED | 1 |
| Vliagoftis, H | 1 |
| Côté, DWJ | 1 |
| Rusznak, M | 1 |
| Peebles, RS | 1 |
| Kuhn, DM | 1 |
| Kovačević, SV | 1 |
| Barać, A | 1 |
| Perić, AV | 1 |
| Jožin, SM | 1 |
| Förster-Ruhrmann, U | 1 |
| Behrbohm, W | 1 |
| Pierchalla, G | 1 |
| Szczepek, AJ | 1 |
| Fluhr, JW | 1 |
| Olze, H | 1 |
| Ono, E | 1 |
| Mita, H | 3 |
| Cleland, EJ | 1 |
| Bassiouni, A | 1 |
| Wormald, PJ | 2 |
| Mullol, J | 2 |
| Picado, C | 3 |
| Karakaya, G | 1 |
| Celebioglu, E | 1 |
| Kalyoncu, AF | 1 |
| Jang, DW | 1 |
| Comer, BT | 1 |
| Lachanas, VA | 1 |
| Kountakis, SE | 3 |
| Steinke, JW | 2 |
| Liu, L | 2 |
| Huyett, P | 1 |
| Negri, J | 1 |
| Payne, SC | 1 |
| Kutlu, A | 1 |
| Salihoglu, M | 1 |
| Haholu, A | 1 |
| Cesmeci, E | 1 |
| Cincik, H | 1 |
| Ozturk, S | 1 |
| Edward, JA | 1 |
| Sanyal, M | 1 |
| Ramakrishnan, VR | 3 |
| Le, W | 1 |
| Nguyen, AL | 1 |
| Kingdom, TT | 3 |
| Hwang, PH | 2 |
| Nayak, JV | 2 |
| Fountain, CR | 2 |
| Mudd, PA | 1 |
| Sillau, SH | 2 |
| Bobolea, I | 1 |
| Cabañas, R | 1 |
| Jurado-Palomo, J | 1 |
| Fiandor, A | 1 |
| Quirce, S | 1 |
| McCarty, JC | 1 |
| Ferguson, BJ | 4 |
| Schmedes, GW | 1 |
| Storck, K | 1 |
| Mulligan, JK | 1 |
| Klimek, L | 3 |
| Dollner, R | 1 |
| Pfaar, O | 1 |
| Parikh, A | 4 |
| Świerczyńska-Krępa, M | 2 |
| Sanak, M | 6 |
| Stręk, P | 2 |
| Ćmiel, A | 1 |
| Szczeklik, A | 4 |
| Niżankowska-Mogilnicka, E | 3 |
| Montone, KT | 1 |
| Cho, KS | 1 |
| Soudry, E | 1 |
| Psaltis, AJ | 1 |
| Nadeau, KC | 1 |
| McGhee, SA | 1 |
| Machado-Carvalho, L | 1 |
| Roca-Ferrer, J | 1 |
| Hoffbauer, S | 1 |
| Au, M | 1 |
| Gupta, MK | 1 |
| Nayan, S | 2 |
| Sethukumar, P | 1 |
| Heywood, R | 1 |
| Narula, A | 1 |
| Dazy, KM | 2 |
| Matsusaka, M | 1 |
| Kabata, H | 1 |
| Fukunaga, K | 1 |
| Suzuki, Y | 1 |
| Masaki, K | 1 |
| Mochimaru, T | 1 |
| Sakamaki, F | 1 |
| Oyamada, Y | 1 |
| Inoue, T | 1 |
| Oguma, T | 1 |
| Sayama, K | 1 |
| Koh, H | 1 |
| Nakamura, M | 1 |
| Umeda, A | 1 |
| Ono, J | 1 |
| Ohta, S | 1 |
| Izuhara, K | 1 |
| Asano, K | 1 |
| Betsuyaku, T | 1 |
| DeConde, AS | 1 |
| Suh, JD | 1 |
| Mace, JC | 1 |
| Alt, JA | 1 |
| Smith, TL | 3 |
| Aryan, Z | 1 |
| Makowska, J | 1 |
| Lewandowska-Polak, A | 2 |
| Wojtczak, A | 1 |
| Skrętkowicz, J | 1 |
| Szabó, K | 1 |
| Polyánka, H | 1 |
| Kiricsi, Á | 1 |
| Révész, M | 1 |
| Vóna, I | 1 |
| Szabó, Z | 1 |
| Bella, Z | 1 |
| Kadocsa, E | 1 |
| Kemény, L | 1 |
| Széll, M | 1 |
| Hirschberg, A | 1 |
| Pezato, R | 1 |
| Holtappels, G | 2 |
| De Ruyck, N | 1 |
| Derycke, L | 1 |
| Van Crombruggen, K | 1 |
| Bachert, C | 5 |
| Pérez-Novo, CA | 1 |
| Zhang, L | 1 |
| Gevaert, P | 3 |
| Krouse, HJ | 1 |
| Krouse, JH | 2 |
| Gitomer, SA | 1 |
| Getz, AE | 1 |
| Adelman, J | 1 |
| McLean, C | 1 |
| Shaigany, K | 1 |
| Makowska, JS | 1 |
| Olszewska-Ziąber, A | 1 |
| Bieńkiewicz, B | 3 |
| Kurowski, M | 1 |
| Woźniakowski, B | 1 |
| Rotkiewicz, A | 1 |
| Dunn, NM | 1 |
| Rebelo, J | 1 |
| Choong, K | 1 |
| Fulford, M | 1 |
| Chan, A | 1 |
| Sakalar, EG | 1 |
| Muluk, NB | 1 |
| Kar, M | 1 |
| Cingi, C | 1 |
| Porcaro, F | 1 |
| Di Marco, A | 1 |
| Cutrera, R | 1 |
| Schleimer, RP | 1 |
| Gudziol, V | 1 |
| Michel, M | 1 |
| Sonnefeld, C | 1 |
| Koschel, D | 1 |
| Hummel, T | 1 |
| Scott, JR | 1 |
| Ernst, HM | 1 |
| Rudmik, L | 1 |
| Dursun, AB | 1 |
| Woessner, KA | 1 |
| Karasoy, D | 1 |
| Einecke, U | 1 |
| Rothe, T | 1 |
| Menz, G | 2 |
| Williams, AN | 1 |
| Yoshimura, T | 1 |
| Yoshikawa, M | 1 |
| Otori, N | 1 |
| Haruna, S | 1 |
| Moriyama, H | 1 |
| Caversaccio, M | 1 |
| Häusler, R | 1 |
| Helbling, A | 1 |
| Das, S | 1 |
| Maeso, PA | 1 |
| Becker, AM | 1 |
| Prosser, JD | 1 |
| Adam, BL | 1 |
| Kim, SH | 2 |
| Yang, EM | 1 |
| Lee, HN | 1 |
| Cho, BY | 1 |
| Ye, YM | 1 |
| Fuentes-Beltrán, A | 1 |
| Montes-Vizuet, R | 1 |
| Valencia-Maqueda, E | 1 |
| Negrete-García, MC | 1 |
| García-Cruz, Mde L | 1 |
| Leunig, A | 1 |
| Braunschweig, F | 1 |
| Havel, M | 1 |
| Markmann, S | 1 |
| Kramer, M | 1 |
| Platt, M | 1 |
| Metson, R | 2 |
| Stankovic, K | 1 |
| Canonica, GW | 1 |
| Casale, TB | 1 |
| Cruz, AA | 1 |
| Lockey, RJ | 1 |
| Zuberbier, T | 1 |
| Jung, H | 1 |
| Cardona, R | 1 |
| Ramírez, RH | 1 |
| Reina, Z | 1 |
| Escobar, MF | 1 |
| Morales, E | 1 |
| Schachtel, BP | 1 |
| Voelker, M | 1 |
| Sanner, KM | 1 |
| Gagney, D | 1 |
| Bey, M | 1 |
| Schachtel, EJ | 1 |
| Becka, M | 1 |
| Ryan, MW | 2 |
| Brooks, EG | 1 |
| Wood, AJ | 1 |
| Douglas, RG | 1 |
| Strand, M | 1 |
| Prasertsuntarasai, T | 1 |
| Leung, R | 1 |
| Zheng, W | 1 |
| Alam, R | 1 |
| Douglas, GC | 1 |
| Karkos, PD | 1 |
| Swift, AC | 1 |
| Rizk, H | 1 |
| Riabova, MA | 1 |
| Shumilova, NA | 1 |
| Fruth, K | 1 |
| Goebel, G | 1 |
| Koutsimpelas, D | 1 |
| Gosepath, J | 4 |
| Schmidtmann, I | 1 |
| Mann, WJ | 4 |
| Brieger, J | 1 |
| Celejewska-Wójcik, N | 1 |
| Mastalerz, L | 2 |
| Wójcik, K | 1 |
| Nieckarz, R | 1 |
| Januszek, R | 1 |
| Hartwich, P | 1 |
| Szaleniec, J | 1 |
| Hydzik-Sobocińska, K | 1 |
| Oleś, K | 1 |
| Cybulska, A | 1 |
| Li, H | 1 |
| Shan, Z | 1 |
| Wang, B | 1 |
| Shikani, AH | 1 |
| Kourelis, K | 1 |
| Rohayem, Z | 1 |
| Basaraba, RJ | 1 |
| Leid, JG | 1 |
| Osame, M | 2 |
| Akiyama, K | 2 |
| Sousa, AR | 1 |
| Scadding, G | 3 |
| Corrigan, CJ | 2 |
| Lee, TH | 3 |
| Arm, JP | 1 |
| Austen, KF | 1 |
| Rosado, A | 1 |
| Vives, R | 1 |
| González, R | 1 |
| Rodríguez, J | 1 |
| DUGAS, M | 1 |
| MILLER, J | 1 |
| ABRUZZI, WA | 1 |
| DE VARENNE, D | 1 |
| Kiełbasa, B | 1 |
| Kawagishi, Y | 1 |
| Higashi, A | 1 |
| Van Zele, T | 2 |
| Watelet, JB | 1 |
| Claeys, G | 1 |
| Claeys, C | 1 |
| van Cauwenberge, P | 2 |
| Amrol, D | 1 |
| Murray, JJ | 1 |
| Corrigan, C | 1 |
| Mallett, K | 1 |
| Ying, S | 2 |
| Roberts, D | 1 |
| Lee, T | 1 |
| Mascia, K | 1 |
| Patrie, J | 1 |
| Hunt, J | 1 |
| Phillips, CD | 1 |
| Koga, T | 1 |
| Oshita, Y | 1 |
| Kamimura, T | 1 |
| Koga, H | 1 |
| Aizawa, H | 1 |
| Ptasinska, A | 1 |
| Jedrzejczak, M | 1 |
| Cieslak, M | 1 |
| Grzegorczyk, J | 2 |
| Pawliczak, R | 2 |
| Dubuske, L | 1 |
| Meng, Q | 1 |
| Lee, JY | 1 |
| Sok, JC | 2 |
| Radojicic, C | 1 |
| Holloway, JW | 1 |
| Shin, HD | 1 |
| Park, CS | 1 |
| Gawlewicz, A | 1 |
| Faber, J | 1 |
| Smith, WB | 1 |
| Macy, E | 1 |
| Castells, MC | 1 |
| Gawchik, SM | 1 |
| Settipane, RA | 1 |
| Wald, J | 1 |
| Robinson, JL | 1 |
| Griest, S | 1 |
| James, KE | 1 |
| Zhang, N | 1 |
| Patou, J | 1 |
| Slavin, RG | 2 |
| Kim, JE | 1 |
| Browne, JP | 1 |
| Slack, R | 1 |
| Lund, V | 1 |
| Brown, P | 1 |
| Durham, SR | 1 |
| Mirakian, R | 1 |
| Jones, NS | 1 |
| Drake-Lee, AB | 1 |
| Ryan, D | 1 |
| Dixon, TA | 1 |
| Huber, PA | 1 |
| Nasser, SM | 1 |
| Joe, SA | 1 |
| Thakkar, K | 1 |
| Stankovic, KM | 1 |
| Goldsztein, H | 1 |
| Reh, DD | 1 |
| Platt, MP | 1 |
| Grevers, G | 1 |
| Pleskow, WW | 3 |
| Mathison, DA | 7 |
| Lumry, WR | 3 |
| Schatz, M | 2 |
| Zeiger, RS | 3 |
| Kirsten, D | 1 |
| Meister, W | 1 |
| Treutler, D | 1 |
| Curd, JG | 2 |
| Enzmann, H | 2 |
| Rieben, FW | 1 |
| Tan, Y | 1 |
| Collins-Williams, C | 1 |
| Schapowal, AG | 1 |
| Simon, HU | 1 |
| Schmitz-Schumann, M | 1 |
| Hamilos, DL | 1 |
| Leung, DY | 1 |
| Wood, R | 1 |
| Cunningham, L | 1 |
| Bean, DK | 1 |
| Yasruel, Z | 1 |
| Schotman, E | 1 |
| Hamid, Q | 1 |
| Swierczyński, Z | 1 |
| Samoliński, B | 1 |
| Krzeski, A | 1 |
| Ogino, S | 1 |
| Abe, Y | 1 |
| Irifune, M | 1 |
| Harada, T | 1 |
| Matsunaga, T | 1 |
| Imamura, I | 1 |
| Fukui, H | 1 |
| Sliwinska-Kowalska, M | 1 |
| Igarashi, Y | 1 |
| White, MV | 1 |
| Wojciechowska, B | 1 |
| Brayton, P | 1 |
| Kaulbach, H | 1 |
| Rozniecki, J | 1 |
| Kaliner, MA | 1 |
| McFadden, EA | 2 |
| Woodson, BT | 1 |
| Massaro, BM | 1 |
| Toohill, RJ | 3 |
| Hankammer, MA | 1 |
| Dias, MA | 1 |
| Biedlingmaier, JF | 1 |
| Kaliner, M | 1 |
| Atamuradov, MA | 1 |
| Garaev, TA | 1 |
| Nakamura, H | 1 |
| Kawasaki, M | 1 |
| Higuchi, Y | 1 |
| Takahashi, S | 1 |
| Ulualp, SO | 1 |
| Sterman, BM | 1 |
| Kaldenbach, T | 1 |
| Schäfer, D | 1 |
| Bittinger, F | 1 |
| Amar, YG | 1 |
| Frenkiel, S | 1 |
| Sobol, SE | 1 |
| Kordek, P | 1 |
| Studniarek, M | 1 |
| Kośny, B | 1 |
| May, A | 1 |
| Wagner, D | 1 |
| Langenbeck, U | 1 |
| Weber, A | 1 |
| Babu, KS | 1 |
| Salvi, SS | 1 |
| Siepmann, M | 1 |
| Kirch, W | 1 |
| Schaefer, D | 1 |
| Amedee, RG | 1 |
| Stern, A | 1 |
| Mardiney, M | 1 |
| Nizankowska, E | 1 |
| Swierczynska, M | 1 |
| Kornatowski, T | 1 |
| Wagrowska-Danilewicz, M | 1 |
| Danilewicz, M | 1 |
| Kühn, H | 1 |
| Spector, SL | 1 |
| Wangaard, CH | 1 |
| Farr, RS | 1 |
| Lockey, RF | 1 |
| Faidi, AR | 1 |
| Tan, EM | 1 |
| Vaughan, JH | 1 |
| Stenius, BS | 1 |
| Lemola, M | 1 |
| Schwartz, LB | 1 |
| Kany, RJ | 1 |
| Fink, JN | 1 |
| Sweet, JM | 1 |
| Knight, A | 1 |
| Jankowski, R | 1 |
| Béné, MC | 1 |
| Moneret-Vautrin, AD | 1 |
| Haas, F | 1 |
| Faure, G | 1 |
| Simon, C | 1 |
| Wayoff, M | 1 |
| Hejjaoui, A | 1 |
| Clauzel, AM | 1 |
| Guérin, B | 1 |
| Dhivert, H | 1 |
| Skassa-Brociek, W | 1 |
| Michel, FB | 1 |
| English, GM | 2 |
| Spector, S | 1 |
| Farr, R | 1 |
| Carr, R | 1 |
| Castillo, JA | 1 |
| Siegel, SC | 1 |
| Rachelefsky, GS | 1 |
| Gorichkina, LA | 1 |
| Frolova, MK | 1 |
| Kuria, VF | 1 |
| Davis, SL | 1 |
| Hadley, RA | 1 |
| Nilsson, DC | 1 |
| Stahl, RH | 1 |
| Debray, H | 1 |
| Galland, A | 1 |
| Settipane, GA | 1 |
| Chafee, FH | 1 |
| Klein, DE | 1 |
| McDonald, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease[NCT01778465] | 7 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study[NCT05009758] | 30 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01287039] | Phase 3 | 489 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01285323] | Phase 3 | 464 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488] | Phase 2 | 11 participants (Actual) | Interventional | 2018-09-05 | Completed | ||
| Improving Patient Care Via Proteomics Based, Microbe-Specific Detection of Chronic Rhinosinusitis[NCT00962689] | 38 participants (Actual) | Observational | 2009-08-31 | Completed | |||
| Challenge Test for Acetylsalicylic Acid Hypersensitivity[NCT01681615] | 50 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | |||
| "Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on Seal to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis"[NCT02557269] | Phase 4 | 60 participants (Actual) | Interventional | 2015-05-31 | Active, not recruiting | ||
| The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases[NCT01867281] | Phase 4 | 32 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis[NCT03472144] | Phase 3 | 60 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Retrospective Review on Patients With Recurrent Asthmatic Attacks Requiring Hospitalizations[NCT04479501] | 2,280 participants (Actual) | Observational | 2017-12-01 | Completed | |||
| A 3 Year Longitudinal Study of the Level of Asthma Control and Treatment of Asthma Patients in Hong Kong[NCT03239431] | 400 participants (Anticipated) | Observational [Patient Registry] | 2017-09-15 | Recruiting | |||
| Determinants of Surgical Outcomes in Chronic Sinusitis[NCT00799097] | 516 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Effect of Thymoquinone and Olive Oil on Wound Healing After Endoscopic Sinus Surgery in Patients With Nasal Polyposis[NCT06070311] | 50 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | |||
| Role of Short Term Systemic Corticosteroid Therapy in the Management of Chronic Rhinosinusitis Without Nasal Polyps[NCT01676415] | Phase 4 | 9 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to participants are no longer receiving intervention due to clinical logistics) | ||
| High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial[NCT02636959] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Manageme[NCT05365841] | 85 participants (Anticipated) | Observational | 2022-05-15 | Not yet recruiting | |||
| Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery[NCT01680705] | 75 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.[NCT05143502] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2022-01-01 | Active, not recruiting | ||
| Randomized, Double-blinded, Placebo-controlled, Prospective, Multicenter Trial to Evaluate the Efficacy and Safety of SIC in Subjects With Mild/Moderate Asthma and Rhinitis/Rhinoconjunctivitis Sensitized to D.Pteronyssinus and/or D. Farinae[NCT04435990] | Phase 3 | 150 participants (Anticipated) | Interventional | 2020-10-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Sino-Nasal Outcome Test (SNOT-22) is a validated 22-item Chronic rhinosinusitis-specific instrument which is scored using a scale where 0=No problem, 1=Very mild problem, 2=Mild or slight problem, 3=Moderate problem, 4=Severe problem, and 5=Problem as bad as it can be. Higher scores on the SNOT-22 survey items suggest worse patient functioning or symptom severity (total score range: 0-110)" (NCT01778465)
Timeframe: 14 days after commencement
| Intervention | score on a scale (Median) |
|---|---|
| Low Salicylate Diet | 44 |
| Normal Diet | 66 |
(NCT01778465)
Timeframe: 14 days after commencement
| Intervention | mmol/L (Median) |
|---|---|
| Low Salicylate Diet | 9.9 |
| Normal Diet | 15.3 |
(NCT01778465)
Timeframe: 14 days after commencement
| Intervention | pg/ml (Median) |
|---|---|
| Low Salicylate Diet | 874.05 |
| Normal Diet | 771.99 |
(NCT01778465)
Timeframe: 14 days after enrollment
| Intervention | ng/ml (Median) |
|---|---|
| Low Salicylate Diet | 0.6 |
| Normal Diet | 0.92 |
(NCT01778465)
Timeframe: 14 days after commencement
| Intervention | ng/ml (Median) |
|---|---|
| Low Salicylate Diet | 44.21 |
| Normal Diet | 23.82 |
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.676 |
| Reslizumab 3.0 mg/kg | -0.941 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.695 |
| Reslizumab 3.0 mg/kg | 0.933 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.109 |
| Reslizumab 3.0 mg/kg | 0.167 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.~The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.110 |
| Reslizumab 3.0 mg/kg | 0.248 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | puffs/day (Least Squares Mean) |
|---|---|
| Placebo | -0.36 |
| Reslizumab 3.0 mg/kg | -0.64 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
| Intervention | CAEs in 52 weeks (Mean) |
|---|---|
| Placebo | 1.804 |
| Reslizumab 3.0 mg/kg | 0.904 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01287039)
Timeframe: Day 1 to Day 478 (longest treatment time plus 2 weeks)
| Intervention | weeks (Median) |
|---|---|
| Placebo | 34.9 |
| Reslizumab 3.0 mg/kg | NA |
The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. (NCT01287039)
Timeframe: Weeks 16, 32, 48 and 52
| Intervention | participants (Number) |
|---|---|
| Reslizumab 3.0 mg/kg | 8 |
"Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.~The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline values correlate to reduced asthma severity." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
| Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
|---|---|---|
| Over first 16 weeks | Over 52 weeks | |
| Placebo | -0.118 | -0.127 |
| Reslizumab 3.0 mg/kg | -0.584 | -0.582 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
| Intervention | CAEs in 52 weeks (Mean) | |
|---|---|---|
| Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
| Placebo | 1.604 | 0.207 |
| Reslizumab 3.0 mg/kg | 0.722 | 0.137 |
An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01287039)
Timeframe: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| At least 1 AE | Mild severity AE | Moderate severity AE | Severe AE | Treatment-related AE | Treatment-related mild AE | Treatment-related moderate AE | Treatment-related severe AE | AE causing patient discontinuation | Serious AE | Deaths | |
| Placebo | 206 | 41 | 133 | 32 | 36 | 23 | 13 | 0 | 8 | 34 | 1 |
| Reslizumab 3.0 mg/kg | 197 | 68 | 107 | 22 | 36 | 24 | 9 | 3 | 4 | 24 | 0 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Uric acid: M>=625, F>=506 μmol/L~Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L~Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L~GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.~Bilirubin: >=34.2 μmol/L~White blood cells: <=3.0 or >20 10^9/L~Hemoglobin: M<=115, F<=95 g/dL~Hematocrit: M<0.37, F<0.32 L/L~Neutrophils: <=1.0 10^9/L~Eosinophils: >10.0 %~Platelets: <75 or >=700 10^9/L~Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood urea nitrogen | Uric acid | Aspartate aminotransferase | Alanine aminotransferase | Gamma-glutamyl transpeptidase | Bilirubin | White blood cells - low | White blood cells - high | Hemoglobin | Hematocrit | Neutrophils | Eosinophils | Platelets - low | Platelets - high | Urinalysis - Blood (hemoglobin) | Urinalysis - Ketones | Urinalysis - Glucose | Urinalysis - Protein | |
| Placebo | 9 | 9 | 1 | 3 | 12 | 2 | 6 | 5 | 7 | 9 | 8 | 135 | 1 | 2 | 32 | 4 | 11 | 32 |
| Reslizumab 3.0 mg/kg | 8 | 6 | 1 | 5 | 12 | 1 | 6 | 3 | 4 | 6 | 6 | 3 | 2 | 0 | 21 | 5 | 14 | 34 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)~Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm~Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm~Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg~Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg~Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg~Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg~Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg~Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute~Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius~Body temp - low >=18 yr: <96.5° F or <35.8° C~Body temp - high >=18 yr: >100.5° Fahrenheit" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sitting pulse - high 12-17 yr | Sitting pulse - low >=18 yr | Sitting pulse - high >=18 yr | Sitting systolic blood pressure - low >=18 yr | Sitting systolic blood pressure - high >=18 yr | Sitting diastolic blood pressure - low 12-17 yr | Sitting diastolic blood pressure - low >=18 yr | Sitting diastolic blood pressure - high >=18 yr | Respiratory rate >=18 yr | Body temperature - low 12-17 yr | Body temperature - low >=18 yr | Body temperature - high >=18 yr | |
| Placebo | 1 | 1 | 5 | 2 | 7 | 1 | 0 | 10 | 3 | 1 | 54 | 0 |
| Reslizumab 3.0 mg/kg | 1 | 0 | 7 | 5 | 7 | 0 | 1 | 5 | 2 | 1 | 49 | 1 |
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.660 |
| Reslizumab 3.0 mg/kg | -0.857 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.777 |
| Reslizumab 3.0 mg/kg | 0.987 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.080 |
| Reslizumab 3.0 mg/kg | 0.115 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.122 |
| Reslizumab 3.0 mg/kg | 0.223 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. During study (Weeks 4, 8, 12 and 16) average value used a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment and visit interaction, and stratification factors as fixed effects and participant as a random effect. Covariates for baseline values were also included in the model; for pulmonary function test analyses, covariates for height and sex were included as well.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.094 |
| Reslizumab 3.0 mg/kg | 0.187 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | SABA puffs per day (Least Squares Mean) |
|---|---|
| Placebo | -0.44 |
| Reslizumab 3.0 mg/kg | -0.50 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
| Intervention | CAEs in 52 weeks (Mean) |
|---|---|
| Placebo | 2.115 |
| Reslizumab 3.0 mg/kg | 0.859 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01285323)
Timeframe: Day 1 to Day 526 (longest treatment time plus 2 weeks)
| Intervention | weeks (Median) |
|---|---|
| Placebo | NA |
| Reslizumab 3.0 mg/kg | NA |
"The blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test. Results of all differential blood tests conducted after randomization were blinded.~The during treatment average eosinophil count was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements. The 'over 16 weeks' value used data from Weeks 4, 8, 12 and 16. The 'over 52 weeks' value used all the during study time points listed in the Time Frame field.~Negative change from baseline values correlate to reduced asthma severity." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
| Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
|---|---|---|
| Over first 16 weeks | Over 52 weeks | |
| Placebo | -0.076 | -0.076 |
| Reslizumab 3.0 mg/kg | -0.555 | -0.565 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
| Intervention | CAEs in 52 weeks (Mean) | |
|---|---|---|
| Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
| Placebo | 1.660 | 0.047 |
| Reslizumab 3.0 mg/kg | 0.646 | 0.033 |
Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion. (NCT01285323)
Timeframe: Baseline visit (prior to reslizumab exposure), Weeks 16, 32, 48 and 52
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 16 | Week 32 | Week 48 | Week 52 | >=1 positive test result | |
| Reslizumab 3.0 mg/kg | 10 | 10 | 10 | 10 | 10 | 15 |
An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01285323)
Timeframe: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Mild TEAE | Moderate TEAE | Severe TEAE | Treatment-related AE | Mild treatment-related AE | Moderate treatment-related AE | Severe treatment-related AE | TEAE causing patient discontinuation | Deaths | Serious AEs | |
| Placebo | 201 | 36 | 140 | 25 | 27 | 14 | 13 | 0 | 9 | 0 | 23 |
| Reslizumab 3.0 mg/kg | 177 | 67 | 98 | 12 | 34 | 22 | 11 | 1 | 8 | 0 | 18 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Creatinine: >=177 μmol/L~Urate: M>=625, F>=506 μmol/L~Aspartate aminotransferase (AST): >=3*upper limit of normal (ULN)~Alanine aminotransferase (ALT): >=3*ULN~GGT = gamma-glutamyl transpeptidase: >= 3*ULN~Total bilirubin: >=34.2 μmol/L~White blood cells (low): <=3.0*10^9/L~White blood cells (high): >=20*10^9/L~Hemoglobin (age >=18 years): M<=115, F<=95 g/dL~Hematocrit (age >=18 years): M<0.37, F<0.32 L/L~Eosinophils/leukocytes: >=10.0%~Platelets: <=75*10^9/L~Neutrophils: <=1.0*10^9/L~Urinalysis: blood, ketones, glucose, and protein: >=2 unit increase from baseline" (NCT01285323)
Timeframe: Week 4 to Week 52
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood urea nitrogen | Creatinine | Urate | AST | ALT | GGT | Bilirubin | Leukocytes (low) | Leukocytes (high) | Hemoglobin | Hematocrit | Eosinophils/leukocytes | Platelets | Neutrophils | Urine blood (hemoglobin) | Urine ketones | Urine glucose | Urine protein | |
| Placebo | 5 | 0 | 5 | 3 | 7 | 11 | 3 | 3 | 0 | 5 | 10 | 168 | 1 | 14 | 28 | 6 | 9 | 28 |
| Reslizumab 3.0 mg/kg | 4 | 1 | 2 | 2 | 3 | 9 | 3 | 10 | 1 | 6 | 8 | 10 | 1 | 9 | 12 | 1 | 7 | 28 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse (high): >100 and increase of >= 30 beats/minute~Sitting systolic blood pressure (low): <90 and decrease of >= 30 mmHg~Sitting systolic blood pressure (high): >160 and increase of >= 30 mmHg~Sitting diastolic blood pressure (low): <50 and decrease of >=12 mmHg (if 12-17 years old: <55 and decrease of >=12 mmHg 0~Sitting diastolic blood pressure (high): >100 and increase of >=12 mmHg~Respiratory rate (low): <6 breaths/minute~Respiratory rate (high): >24 and increase of >=10 breaths/minute~Body temperature (low): <35.8° Celsius~Body temperature (high): >=38.1 and increase of >=1.1° Celsius" (NCT01285323)
Timeframe: Week 4 to Week 52
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| >=1 postbaseline vital sign abnormality | Sitting pulse (high) | Sitting systolic blood pressure (low) | Sitting systolic blood pressure (high) | Sitting diastolic blood pressure (low) | Sitting diastolic blood pressure (high) | Respiratory rate (low) | Respiratory rate (high) | Body temperature (low) | Body temperature (high) | |
| Placebo | 58 | 6 | 2 | 0 | 4 | 3 | 0 | 4 | 50 | 1 |
| Reslizumab 3.0 mg/kg | 49 | 6 | 1 | 1 | 3 | 4 | 1 | 5 | 39 | 0 |
The medication side-effect and compliance inventory is a questionnaire to evaluate the frequency and severity of common side effects associated with the medications used in this study. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone | 0 |
| Topical Mometasone | 0 |
Change from baseline in individual symptom severity. The taskforce symptom inventory is a visual analog scale of the severity of the 4 major symptoms making up the clinical diagnostic criteria of CRS. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone | 0 |
| Topical Mometasone | 0 |
"The Sino-nasal Outcome Test-22 is a validated questionnaire that measures 22 nasal and quality of life symptoms (nasal obstruction and loss of smell and taste) ranked from 0 (not a problem) to 5 (problem as bad as it can be).~Min score= 0, Max score= 110 (worst possible problem on all symptoms)~Change from baseline of the SNOT-22 score. The SNOT-22 questionnaire is a 22-item disease-specific health related quality of life instrument validated for use in chronic rhinosinusitis." (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 4-6 WEEKS | 3 MONTHS | |
| Prednisone | 45.75 | 49 |
| Topical Mometasone | 34.4 | 34.4 |
65 reviews available for aspirin and Sinusitis
| Article | Year |
|---|---|
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Aspirin; Chronic Disease; Humans; Nasa | 2022 |
New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Basophils; Humans; Nasal Polyps; Sinusitis | 2022 |
Treatment options for chronic rhinosinusitis with nasal polyps.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspirin; Asthma; Biological Products; Chronic Diseas | 2021 |
Updates on treatment options in aspirin exacerbated respiratory disease.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Cytokines; Humans; Sinusitis | 2022 |
Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
Aspirin-Exacerbated Respiratory Disease: A Unique Case of Drug Hypersensitivity.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2022 |
Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; | 2023 |
A Review of Aspirin-exacerbated Respiratory Diseases and Immunological Efficacy of Aspirin Desensitization.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nas | 2022 |
Relationship Between Alcohol Intolerance and Aspirin-Exacerbated Respiratory Disease (AERD): Systematic Review.
Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Desensitization, Immunologic; Humans; Nas | 2023 |
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; Nasal Polyps | 2023 |
The chronic rhinosinusitis practice parameter.
Topics: Advisory Committees; Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; | 2023 |
Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhinitis; Sinu | 2020 |
Comorbidities associated with eosinophilic chronic rhinosinusitis: A systematic review and meta-analysis.
Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Eosinophilia; Humans; Nasal Polyps; Rhinitis; Severit | 2020 |
[Widal's triad : clinical manifestations, pathophysiology and therapeutic advances].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyp | 2020 |
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy,
Topics: Administration, Oral; Algorithms; Allergens; Animals; Anti-Inflammatory Agents; Aspirin; Asthma, Asp | 2021 |
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, | 2021 |
Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Nasal Polyps; Sin | 2021 |
Aspirin exacerbated respiratory disease: Current topics and trends.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arachidonic Acid; Aspirin; A | 2018 |
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Chronic Disea | 2019 |
Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bl | 2019 |
Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respi | 2013 |
Identifying asthma triggers.
Topics: Allergens; Aspirin; Asthma; Disease Progression; Female; Gastroesophageal Reflux; Humans; Male; Prog | 2014 |
Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Human | 2014 |
The molecular genetics of inflammatory, autoimmune, and infectious diseases of the sinonasal tract: a review.
Topics: Aspirin; Autoimmune Diseases; Churg-Strauss Syndrome; Granulomatosis with Polyangiitis; Humans; Infe | 2014 |
Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity.
Topics: Animals; Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Receptors, Prostaglandin E, E | 2014 |
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Desensitization, Immunologic; Hum | 2015 |
Aspirin-exacerbated respiratory disease: characteristics and management strategies.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhini | 2015 |
Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Humans; Rh | 2015 |
[Hypersensitivity to acetylsalicylic acid].
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Incidence; Nasal Polyps; Rhinitis; | 2015 |
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Aspirin; Asthma; Comorbidity; DNA, Catalytic; Drug Hyperse | 2015 |
The Role of Surgery in Management of Samter's Triad: A Systematic Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Endoscopy; Humans; | 2016 |
Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease.
Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Disease Progre | 2016 |
Aspirin-exacerbated respiratory disease and current treatment modalities.
Topics: Algorithms; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, H | 2017 |
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Respiratory Tract Disease | 2016 |
Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nasal Polyp | 2017 |
Current complications and treatment of aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2016 |
The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.
Topics: Administration, Oral; Aspirin; Chronic Disease; Desensitization, Immunologic; Humans; Lysine; Nasal | 2008 |
Aspirin sensitivity and desensitization for asthma and sinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase Inhibitors; Drug Hypersensi | 2009 |
Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Gene Expression Profiling; Humans; Nasal Po | 2009 |
[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options].
Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypers | 2009 |
[Allergy and intolerance to nonsteroidal antinflammatory drugs: successful desensitization in three cases].
Topics: Adult; Anaphylaxis; Angioedema; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2009 |
Rhinosinusitis and comorbidities.
Topics: Anti-Bacterial Agents; Aspirin; Cystic Fibrosis; Humans; Hypersensitivity; Immunity, Humoral; Immuno | 2010 |
Pathogenesis and treatment of chronic rhinosinusitis.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bi | 2010 |
Role of aspirin desensitization in the management of chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps; | 2011 |
Aspirin intolerance and the cyclooxygenase-leukotriene pathways.
Topics: Aspirin; Asthma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Desensiti | 2004 |
Categorization of eosinophilic chronic rhinosinusitis.
Topics: Aspergillosis, Allergic Bronchopulmonary; Aspirin; Child; Chronic Disease; Eosinophilia; Eosinophils | 2004 |
Alternative medical treatment strategies for chronic hyperplastic eosinophilic sinusitis.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Aspirin; Chronic Disease; Eosino | 2005 |
Current concepts in therapy of chronic rhinosinusitis and nasal polyposis.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspirin; Chronic Disease; Endoscopy; Eosinophilia; Histami | 2005 |
Differential diagnosis of eosinophilic chronic rhinosinusitis.
Topics: Animals; Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Fungi; Humans; Hypersensit | 2006 |
Sinusitis: allergies, antibiotics, aspirin, asthma.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Platelet Aggregation Inhibitors; Rhinitis, Allergic, | 2006 |
Selection of patients for aspirin desensitization treatment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Drug Hyperse | 2006 |
Differential diagnosis of eosinophilic chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Eosinophils; Humans; Mycoses; Rhini | 2007 |
Aspirin-sensitive rhinosinusitis and asthma.
Topics: Arachidonic Acid; Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Infl | 2007 |
Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis.
Topics: Animals; Aspirin; Chronic Disease; Enterotoxins; Humans; Immunoglobulin E; Mice; Nasal Mucosa; Nasal | 2007 |
Medical management of rhinosinusitis comorbidities-asthma, aspirin sensitivity, gastroesophageal reflux, immune deficiencies.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Eosinophils; Gastroesophageal Reflux; Humans; Immunologic De | 2007 |
Chronic rhinosinusitis and asthma.
Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Drug Hypersensitivity; Humans; Lymphocytes; Nasal Muc | 2008 |
Diseases associated with chronic rhinosinusitis: what is the significance?
Topics: Aspirin; Chronic Disease; Cystic Fibrosis; Humans; Hypersensitivity; Immunocompromised Host; Inciden | 2008 |
Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1995 |
[The classification of nonallergic eosinophilic rhinitis and sinus].
Topics: Age Factors; Aspirin; Asthma; Drug Tolerance; Eosinophils; Humans; Nasal Polyps; Neutrophils; Rhinit | 1994 |
Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Humans; Nasal Polyps; R | 2000 |
Aspirin and asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Asthma; Bronchial Hyperreactivi | 2000 |
Aspirin-induced rhinitis and asthma.
Topics: Aspirin; Asthma; Eicosanoids; Glutathione Transferase; Humans; Rhinitis; Sinusitis | 2001 |
Sheldon Memorial Lecture. Medical management of nasal polyps and sinusitis.
Topics: Adrenal Cortex Hormones; Aspirin; Humans; Nasal Polyps; Sinusitis | 1991 |
Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review.
Topics: Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis | 1989 |
Continuing medical education. Asthma in infants and children: Part 1.
Topics: Airway Resistance; Allergens; Aspirin; Asthma; Asthma, Exercise-Induced; Bronchi; Child; Child, Pres | 1985 |
16 trials available for aspirin and Sinusitis
| Article | Year |
|---|---|
Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; | 2023 |
Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Cross- | 2021 |
The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.
Topics: Adult; Anti-Asthmatic Agents; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Double-Blind Method | 2021 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery.
Topics: Adult; Aspirin; China; Chronic Disease; Double-Blind Method; Endoscopy; Female; Humans; Male; Middle | 2019 |
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
Topics: Administration, Oral; Adult; Aged; Allergens; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Dise | 2014 |
Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study.
Topics: Adult; Aged; Aspirin; Asthma; Cross-Over Studies; Desensitization, Immunologic; Drug Hypersensitivit | 2015 |
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, I | 2015 |
Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; C | 2016 |
Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Aspirin; Common Cold; Dose-Response Relationship, Drug; | 2010 |
The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Chronic Disease; | 2010 |
Topical gel therapy for sinonasal polyposis in Samter's triad: preliminary report.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Asth | 2012 |
Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis.
Topics: Adult; Aged; Aspirin; Asthma; Biopsy; Desensitization, Immunologic; Down-Regulation; Drug Hypersensi | 2002 |
Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.
Topics: Aspirin; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Hypersensitivity; Forced Expira | 1984 |
[Point scale quantification of changes in computed tomography of chronic hyperplastic rhinosinusitis].
Topics: Adult; Aspirin; Chronic Disease; Humans; Image Processing, Computer-Assisted; Middle Aged; Paranasal | 2000 |
Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma.
Topics: Adolescent; Adult; Aged; Aging; Airway Obstruction; Aspirin; Asthma; Azo Compounds; Benzenesulfonate | 1976 |
183 other studies available for aspirin and Sinusitis
| Article | Year |
|---|---|
A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Lysine; Nasal | 2022 |
Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aspirin; Chronic Dis | 2021 |
Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
Topics: Adrenal Cortex Hormones; Aspirin; Asthma, Aspirin-Induced; Budesonide; Chronic Disease; Humans; Nasa | 2022 |
Urinary leukotriene E4 is a biomarker for chronic rhinosinusitis associated with leukotriene dysregulation irrespective of aspirin sensitivity status.
Topics: Aspirin; Biomarkers; Chronic Disease; Humans; Leukotriene E4; Leukotrienes; Sinusitis | 2022 |
Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2022 |
Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
Topics: Aspirin; Asthma, Aspirin-Induced; Body Mass Index; Humans; Leukotriene E4; Respiratory System; Sinus | 2022 |
Steroid affected cytokines in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Cytokines; Granulocyte-Macrophage Colony-Stimulating Factor; Human | 2022 |
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
Topics: Antibodies, Monoclonal, Humanized; Arthralgia; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Hu | 2022 |
Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Desensitization, Immunologic; Female; Humans; | 2022 |
Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Humans; Mucus | 2022 |
Comprehensive Analysis of Nasal Polyps Reveals a More Pronounced Type 2 Transcriptomic Profile of Epithelial Cells and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eosinophilia; Epithelial Cells; Humans; Inflammat | 2022 |
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eicosanoids; Humans; Nasal Polyps; Prostaglandins | 2022 |
If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biological Products; Huma | 2022 |
Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.
Topics: Anosmia; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Mental Health; Quality of Life; Sinusitis | 2022 |
Hypereosinophilia following aspirin desensitization for aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2022 |
Inheritance of NSAID-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Nasal Pol | 2023 |
Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2022 |
Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biological Products; Huma | 2022 |
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Aspirin; Biological Products; Chronic Disease; | 2023 |
Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Humans; Inflammation Mediators; Nasal Pol | 2023 |
Algorithmic Identification of Patients With Aspirin-Exacerbated Respiratory Disease Using an Electronic Health Record.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Electronic Health Records | 2023 |
Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia.
Topics: Aspirin; Asthma; Chronic Disease; Cross-Sectional Studies; Female; Humans; Male; Nasal Polyps; Preva | 2023 |
Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Dinoprostone; Eicosanoids; Homeostasis; Humans; Leukotrie | 2023 |
Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Eosinophilia; Eosinophils; Humans; Sinusitis | 2023 |
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal | 2023 |
Readability and quality analysis of patient education materials in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Comprehension; Humans; Patient Education as Topic; Sinusitis | 2023 |
Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Cardiovascular Di | 2023 |
Eosinophilic granulomatosis with polyangiitis presenting as aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Churg-Strauss Syndrome; Granulomatosis with Polyangiitis; Humans; | 2023 |
Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Eicosanoids; Humans; Hydroxyeicosatetra | 2023 |
Angiogenesis and eosinophilia in the nasal mucosa of patients with different clinical phenotypes of chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Cross-Sectional Studies; Eosinophilia; Humans; Nasal Mucosa; Nasal Polyps; | 2023 |
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.
Topics: Adult; Aged; Allergens; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin | 2019 |
A graduated approach to management of chronic rhinosinusitis in aspirin-exacerbated respiratory disease in the era of precision medicine.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Humans; Precision Medicine; Sinusitis | 2019 |
The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Bodily Secretions; Chronic Disease; Cytokines; Desensitizat | 2020 |
Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Human | 2022 |
Analysis of the impact of bronchial asthma and hypersensitivity to aspirin on the clinical course of chronic sinusitis with nasal polyps.
Topics: Adult; Aspirin; Asthma; Bronchial Hyperreactivity; Case-Control Studies; Drug Hypersensitivity; Fema | 2019 |
Eosinophilic Asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Child; Humans; Hypersensitivit | 2020 |
Aspirin-Exacerbated Respiratory Disease With Allergic Fungal Rhinosinusitis: A Case Series of Overlapping Sinonasal Endotypes.
Topics: Allergens; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female; | 2020 |
Aspirin-exacerbated respiratory disease: longitudinal assessment of a large cohort and implications of diagnostic delay.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Delayed Diagnosis; Humans | 2020 |
IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
Topics: Adult; Aged; Antibodies; Aspirin; Female; Humans; Immunoglobulin E; Immunoglobulin G; Interleukin-5; | 2020 |
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2020 |
A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bronchiectasis; Humans; R | 2020 |
Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Endoscopy; Humans; Nasal Polyps; Retrospective St | 2020 |
Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice.
Topics: Adult; Aspirin; Asthma; Cell Biology; Chronic Disease; Comorbidity; Cross-Sectional Studies; Female; | 2020 |
Aspirin-exacerbated respiratory disease: personalized medical and surgical approaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2020 |
A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Retrospective Studies; Rhin | 2021 |
Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Retrospective | 2021 |
Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Exanthema; Humans; Leukot | 2020 |
Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2020 |
Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Bronchoalveolar L | 2021 |
A multicenter approach to evaluate omalizumab effectiveness in Samter's triad.
Topics: Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma | 2020 |
[Aspirin-exacerbated respiratory disease: current diagnosis and treatment].
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Respiratory Tract Diseases; | 2020 |
Level of sex hormones and their association with acetylsalicylic acid intolerance and nasal polyposis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Cone-Beam Computed Tomography; Drug Hypers | 2020 |
Dysbiosis in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Dysbiosi | 2021 |
Multidisciplinary single-center outcomes compared to two-center outcomes for the treatment of aspirin exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Respiratory Tract | 2021 |
Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Humans; Sinusitis | 2021 |
Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis | 2021 |
COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; COVID-19; Humans; Respira | 2021 |
Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD).
Topics: Aspirin; Biomarkers; Chronic Disease; Disease Progression; Disease Susceptibility; Humans; Nasal Pol | 2021 |
Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; E | 2021 |
Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end?
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Eosinophilia; Female; Humans; Male; Middle Aged; Nasal Muc | 2017 |
Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Immunoglobulin G; Male; Middle Aged; Nasal Polyps; Respira | 2017 |
Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2018 |
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2018 |
Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study.
Topics: Administration, Inhalation; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cross-Sectional | 2018 |
Differences in urinary leukotriene E4 levels and distribution of eosinophils between chronic rhinosinusitis patients with aspirin-intolerant and-tolerant asthma.
Topics: Aspirin; Asthma; Chronic Disease; Drug Tolerance; Eosinophils; Humans; Leukotriene E4; Rhinitis; Sin | 2016 |
A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Desensitization, Immunologic; Eosinophi | 2019 |
A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cyclooxygenase Inhibitors; Desensitization, Immun | 2019 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2018 |
Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.
Topics: Aged; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cohort Studies; Desensitization, Immunologi | 2019 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2018 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2018 |
Aspirin Desensitization: Faster Protocols for Busy Patients.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Sinusitis | 2019 |
[Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; | 2019 |
The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients.
Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Nasal Polyps; Pseu | 2013 |
Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Drug Eruptions; Dr | 2013 |
Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; | 2014 |
Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Cysteine; Cytokines; Eosinophils; Female; Humans; Interfer | 2013 |
Short-term beneficial effect of aspirin in patient with chronic rhinosinusitis and tolerant to acetylsalicylic acid.
Topics: Adult; Aspirin; Chronic Disease; Humans; Male; Rhinitis; Sinusitis | 2013 |
Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients.
Topics: Adult; Aged; Aspirin; Chronic Disease; Ethmoid Sinus; Female; Flow Cytometry; Glucocorticoids; Granu | 2013 |
Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Drug Resistance; Eosinophils; Fe | 2013 |
Concurrent coxibs and anti-platelet therapy unmasks aspirin-exacerbated respiratory disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 2 Inhibitors; Dyslipi | 2013 |
Impact of vitamin D deficiency upon clinical presentation in nasal polyposis.
Topics: Age Factors; Allergens; Antigens, Fungal; Aspirin; Black or African American; Cholecalciferol; Chron | 2014 |
Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?
Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug Tolerance; Human | 2014 |
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitizat | 2014 |
Samter's triad with aural involvement: a novel approach to management.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Drug Hypersensitiv | 2014 |
Phenotype of asthma related with high serum periostin levels.
Topics: Adult; Asian People; Aspirin; Asthma; Cell Adhesion Molecules; Cytokines; Drug Tolerance; Eosinophil | 2015 |
Outcomes of complete vs targeted approaches to endoscopic sinus surgery.
Topics: Aspirin; Asthma; Chronic Disease; Endoscopy; Female; Humans; Male; Middle Aged; Nasal Polyps; Postop | 2015 |
A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians.
Topics: Adolescent; Adult; Aged; Alleles; Aspirin; Case-Control Studies; Chromosomes, Human, Pair 6; Chronic | 2015 |
Samter's Triad to Aspirin-Exacerbated Respiratory Disease: Historical Perspective and Current Clinical Practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2015 |
Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.
Topics: Aspirin; Asthma; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dinoprostone; Homeostasis; Humans; Nas | 2016 |
Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Eosinophilia; Female; Humans; Male; Middle | 2016 |
Clinical benefits of aspirin desensitization in patients with nonsteroidal anti-inflammatory drug exacerbated respiratory disease are not related to urinary eicosanoid release and are accompanied with decreased urine creatinine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Creatine; Desensitization, Immunolo | 2016 |
To anticoagulate? Controversy in the management of thrombotic complications of head & neck infections.
Topics: Adolescent; Anticoagulants; Aspirin; Cavernous Sinus Thrombosis; Cerebral Angiography; Child; Child, | 2016 |
Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Female; Human | 2017 |
Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cross-Sectional Studies; Female; Humans; L | 2017 |
Response to "The Role of Surgery in Management of Samter's Triad: A Systematic Review".
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Nasal Polyps; Sinusitis | 2017 |
Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aspirin; Chronic Disease; Evidence-Based Medicine; Hu | 2017 |
Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis.
Topics: Administration, Oral; Adult; Age Factors; Aspirin; Asthma; Drug Hypersensitivity; Female; Forced Exp | 2008 |
[From wheezing to anaphylactic shock: allergology for your practice].
Topics: Adult; Allergy and Immunology; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2008 |
[Nonallergic diseases of the upper and lower airways].
Topics: Aspirin; Asthma; Bronchitis; Diagnosis, Differential; Drug Hypersensitivity; Eosinophilia; Humans; I | 2008 |
Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma.
Topics: Adult; Aged; Aspirin; Asthma; Cell Extracts; Chronic Disease; Dinoprostone; Drug Hypersensitivity; E | 2008 |
Otologic manifestations in Samter's syndrome.
Topics: Aspirin; Asthma; Chronic Disease; Cohort Studies; Drug Hypersensitivity; Ear Diseases; Ear, Middle; | 2009 |
Proteomics blood testing to distinguish chronic rhinosinusitis subtypes.
Topics: Aspirin; Asthma; Biomarkers; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Fungi; | 2008 |
Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis.
Topics: Adult; Alleles; Aspirin; Asthma; Drug Hypersensitivity; Epistasis, Genetic; Female; Gene Frequency; | 2009 |
Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients.
Topics: Administration, Intranasal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chemoki | 2009 |
[Chronic rhinosinusitis and aspirin intolerance].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Spasm; Desensitization, I | 2009 |
Unmet needs in severe chronic upper airway disease (SCUAD).
Topics: Allergens; Aspirin; Child; Chronic Disease; Drug Hypersensitivity; Humans; Nasal Polyps; Prevalence; | 2009 |
Aspirin sensitivity and the nose.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Nasal Polyps; Respiration Disorders | 2010 |
[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad].
Topics: Aspirin; Asthma; Humans; Nasal Polyps; Rhinitis; Sinusitis; Suppuration | 2011 |
Low SPINK5 expression in chronic rhinosinusitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; | 2012 |
Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Humans; Leukotriene E4; Male | 2012 |
[Expressions of EOS and COX-2 in nasal polyps in patients with aspirin triad syndrome and its significance].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 2; Endoscopy; Eosino | 2012 |
Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2012 |
A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Control Studies; Drug Hypersensitivit | 2002 |
Leukotriene receptors and aspirin sensitivity.
Topics: Aspirin; Asthma; Desensitization, Immunologic; Down-Regulation; Drug Hypersensitivity; Humans; Membr | 2002 |
Can NSAIDs intolerance disappear? A study of three cases.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Forced Expir | 2003 |
[THERAPEUTIC USE OF THE COMBINATION OF CHYMOTRYPSIN WITH ACETYLSALICYLIC ACID IN PEDIATRICS].
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Bronchitis; Child; Chymotrypsin; Fever; | 1963 |
COMPARATIVE EFFECTIVENESS OF THREE ORAL MEDICATIONS IN SINUSTIS AND RHINITIS; A DOUBLE-BLIND STUDY.
Topics: Anti-Allergic Agents; Aspirin; Biomedical Research; Codeine; Double-Blind Method; Headache; Histamin | 1964 |
[VALUE OF CHYMALGYL IN OTORHINOLARYNGOLOGICAL PATHOLOGY. APROPOS OF 20 CASES].
Topics: Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antipyretics; Aspirin; Drug Therapy; | 1965 |
Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Contr | 2004 |
Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Enterotoxins; Female; Humans; Immuno | 2004 |
Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Epithelial Cells; Fe | 2005 |
Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease.
Topics: Adult; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cohort Studies; Drug Hypersensitivity | 2005 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest).
Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Hydroxyeicosatetraenoic Acids; | 2005 |
The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Anti-Inflammatory Agents, N | 2005 |
Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Chronic Disease; Drug Hyperse | 2006 |
Does it make sense to "desens"? Aspirin desensitization in the treatment of chronic rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Desensitization, Immunolo | 2006 |
Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Female; Gene | 2007 |
Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Drug Hypersensitivity; E | 2006 |
Allergy and sinus disease.
Topics: Anti-Allergic Agents; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respiratory Hypersensiti | 2006 |
Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Drug Hyperse | 2007 |
Impact of aspirin intolerance on outcomes of sinus surgery.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Chronic Dise | 2007 |
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Child, Preschool; Chronic Diseas | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
BSACI guidelines for the management of rhinosinusitis and nasal polyposis.
Topics: Aspirin; Child; Churg-Strauss Syndrome; Female; Humans; Male; Nasal Polyps; Rhinitis; Sinusitis | 2008 |
Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma.
Topics: Adipokines; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Carrier Proteins; Chrom | 2008 |
[ASA-intolerance (Samter's syndrome): an important differential diagnosis for chronic airway diseases].
Topics: Aspirin; Asthma; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Humans; Nasal Poly | 2008 |
[Inhalation provocation test with lysine acetylsalicylic acid (Aspisol)--a useful method for the diagnosis of analgesic asthma].
Topics: Airway Resistance; Analgesics; Aspirin; Asthma; Bronchi; Bronchial Provocation Tests; Drug Hypersens | 1984 |
Aspirin-sensitive asthma and rhinosinusitis: current concepts and recent advances.
Topics: Adult; Aspirin; Asthma; Desensitization, Immunologic; Drug Tolerance; Humans; Rhinitis; Sinusitis | 1984 |
[Rhinosinusitis polyposa and intolerance to analgesics (aspirin intolerance)].
Topics: Adult; Aged; Analgesics; Aspirin; Bronchial Provocation Tests; Drug Hypersensitivity; Drug Tolerance | 1983 |
Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration.
Topics: Adult; Aged; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Indometha | 1983 |
Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Forced Exp | 1983 |
Aspirin-induced asthma in children.
Topics: Acetylation; Adolescent; Anti-Inflammatory Agents; Aspirin; Asthma; Child; Complement System Protein | 1982 |
Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis.
Topics: Adolescent; Adult; Aspirin; Cell Movement; Cytokines; Drug Hypersensitivity; Eosinophilia; Eosinophi | 1995 |
Histamine metabolism in nasal polyps.
Topics: Amine Oxidase (Copper-Containing); Aspirin; Asthma; Bronchial Provocation Tests; Histamine; Histamin | 1993 |
Nasal secretions in response to acetylsalicylic acid.
Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Inflammation; Male; Middle Aged | 1993 |
Orbital complications of sinusitis in the aspirin triad syndrome.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Orbita | 1996 |
Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes.
Topics: Adult; Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Outcome Assessm | 1996 |
Ketorlac-induced status asthmaticus after endoscopic sinus surgery in a patient with Samter's triad.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Endoscopy; F | 1997 |
Medical management of sinusitis.
Topics: Adrenal Cortex Hormones; Aspirin; Drainage; Humans; Hypersensitivity; Nasal Decongestants; Nasal Sep | 1998 |
[A case of aspirin triad].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Follow-Up | 1999 |
Effects of sinus surgery on asthma in aspirin triad patients.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Airway Resistance; Aspirin; Asthma; Chro | 1999 |
Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease.
Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Indoles; Leu | 1999 |
[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa].
Topics: Adult; Aged; Aspirin; Drug Hypersensitivity; Eosinophilia; Eosinophils; Female; Humans; Male; Middle | 1999 |
Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter's triad.
Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease | 2000 |
[Family study of patients with aspirin intolerance and rhinosinusitis].
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation T | 2000 |
Drug Points: tachycardia associated with moxifloxacin.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Aza Compounds; Bronchitis; | 2001 |
Individual monitoring of aspirin desensitization.
Topics: Adult; Aged; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Male; Mid | 2001 |
[Cellular antigen stimulation test (CAST). A new possibility in diagnosis of aspirin-sensitivity rhinosinusitis?].
Topics: Aspirin; Drug Hypersensitivity; Enzyme-Linked Immunosorbent Assay; Humans; Leukocytes; Leukotriene C | 2001 |
Aspirin desensitization for chronic hyperplastic sinusitis, nasal polyposis, and asthma triad.
Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; | 2001 |
Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelo | 2002 |
[Rhinosinusitis polyposa as the only symptom of aspirin intolerance -- a rhinorheomanometric diagnosis (author's transl)].
Topics: Aspirin; Drug Hypersensitivity; Female; Humans; Manometry; Maxillary Sinus; Middle Aged; Nasal Polyp | 1977 |
Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges.
Topics: Anti-Inflammatory Agents; Aspirin; Asthma; Bronchial Provocation Tests; Drug Hypersensitivity; Human | 1979 |
Aspirin and concomitant idiosyncrasies in adult asthmatic patients.
Topics: Acetaminophen; Administration, Oral; Adolescent; Adult; Aged; Aspirin; Asthma; Azo Compounds; Drug H | 1979 |
Aspirin-improved ASA triad.
Topics: Aspirin; Asthma; Female; Humans; Middle Aged; Nasal Polyps; Sinusitis | 1978 |
Aspirin intolerance in asthmatic patients: case histories.
Topics: Adult; Aspirin; Asthma; Female; Humans; Rhinitis; Sinusitis | 1977 |
Provoking factors in bronchial asthma.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Bronchitis; Child; Child, Preschool; Drug Hypersensitivity | 1975 |
Tryptase and histamine release during aspirin-induced respiratory reactions.
Topics: Administration, Oral; Adult; Aspirin; Asthma; Forced Expiratory Volume; Histamine; Histamine Release | 1991 |
Surgery for sinusitis and aspirin triad.
Topics: Adolescent; Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Follow-Up Studie | 1990 |
Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Asthma; Combined Modality Therapy; Desensitization, Immunol | 1990 |
Immunohistological characteristics of nasal polyps. A comparison with healthy mucosa and chronic sinusitis.
Topics: Adolescent; Adult; Aged; Antigen-Antibody Complex; Aspirin; Asthma; Complement System Proteins; Drug | 1989 |
Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.
Topics: Adolescent; Adult; Aged; Allergens; Animals; Antigens, Dermatophagoides; Aspirin; Asthma; Child; Chi | 1988 |
Histopathology and immunofluorescent immunoglobulins in asthmatics with aspirin idiosyncrasy.
Topics: Adult; Aspirin; Asthma; Drug Hypersensitivity; Female; Fluorescent Antibody Technique; Humans; Immun | 1987 |
Prevalence of aspirin intolerance in asthmatics treated in a hospital.
Topics: Aspirin; Asthma; Bronchial Provocation Tests; Drug Hypersensitivity; Female; Hospitalization; Humans | 1986 |
Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy.
Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Chronic Disease; Drug Hypersensitiv | 1986 |
[Diagnostic and therapeutic methods in the asthmatic triad].
Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Child; Desensitization, Immunologic | 1985 |
Aspirin disease and adverse effects.
Topics: Adult; Aspirin; Asthma; Blood Platelet Disorders; Female; Gastrointestinal Hemorrhage; Humans; Male; | 1971 |
Allergic disorders of the nose and paranasal sinuses.
Topics: Aspirin; Drug Hypersensitivity; Dust; Humans; Nasal Polyps; Pollen; Rhinitis, Allergic, Seasonal; Si | 1974 |
[A new anti-inflammatory agent: calcium bucloxate in pediatrics].
Topics: Adolescent; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Bronchopneumonia; | 1974 |
Aspirin intolerance. II. A prospective study in an atopic and normal population.
Topics: Allergens; Angioedema; Aspirin; Asthma; Bronchial Spasm; Drug Hypersensitivity; Female; Humans; Male | 1974 |
Aspirin intolerance in asthma. Detection by oral challenge.
Topics: Adult; Aspirin; Asthma; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Male; Polyps; Respir | 1972 |